Pain Following Spinal Cord Injury

Swati Mehta MA
Robert Teasell MD FRCPC
Eldon Loh MD FRCPC
Christine Short MD FRCPC
Dalton L Wolfe PhD
Jane TC Hsieh MSc
Key Points

Pain post SCI has a significant effect of quality of life.

Post-SCI pain is common and often severe beginning relatively early post-injury.

Post-SCI pain is most commonly divided into neuropathic or musculoskeletal pain.

Massage may not be helpful for post-SCI neuropathic and musculoskeletal pain.

Osteopathy alone may not be helpful for post-SCI neuropathic pain.

Acupuncture may reduce post-SCI neuropathic and musculoskeletal pain.

Electrostimulation acupuncture is effective in improving neuropathic pain in SCI pain.

Regular exercise reduces post-SCI neuropathic and musculoskeletal pain.

A shoulder exercise protocol reduces post-SCI nociceptive shoulder pain intensity.

MAGIC wheels 2 gear wheelchair reduces nociceptive shoulder pain.

Hypnosis may reduce neuropathic and musculoskeletal pain intensity post SCI.

Biofeedback may reduce neuropathic and musculoskeletal pain intensity post SCI.

Cognitive behavioral therapy combined with pharmacological treatment may result in improvement in secondary outcomes among SCI individuals with chronic pain.


Visual imagery may reduce neuropathic pain post SCI

Transcranial electrical stimulation is effective in reducing post SCI neuropathic pain.

Static field magnet may reduce nociceptive shoulder pain post SCI.

Transcutaneous electrical nerve stimulation may reduce pain at site of injury in patients with thoracic but not cervical injury.

Transcranial magnetic stimulation reduces post-SCI neuropathic pain.

Gabapentin and pregabalin improve neuropathic pain post SCI.

Combined osteopathy and pregabalin may improve pain post SCI.

Lamotrigine may improve neuropathic pain in incomplete spinal cord injury

Levetiracetam is not effective in reducing neuropathic pain post SCI.

Valproic acid does not reduce neuropathic pain post SCI.

Amitriptyline is effective in reducing neuropathic pain in depressed SCI individuals.
Duloxetine may improve neuropathic pain post SCI.

Trazodone does not reduce post-SCI neuropathic pain.

Lidocaine through a subarachnoid lumbar catheter and intravenous Ketamine improve post-SCI neuropathic pain short term.

Mexilitene does not improve SCI dysesthetic pain.

Intrathecal Baclofen improves musculoskeletal pain post SCI and may help dysesthetic pain related to spasticity.

Motor point phenol block reduces spastic shoulder pain.

Botulinum toxin injections for focal spasticity improves pain.

Intravenous morphine reduces mechanical allodynia.

Tramadol reduces neuropathic pain.

Alfentanil reduces chronic pain post SCI.

Alfentanil is more effective in reducing wind up like pain post SCI than ketamine.

Oxycodone and anticonvulsants may improve neuropathic SCI pain.

Cannabinoids are a potential new treatment for post-SCI pain in need of further study.

Dronabinal is not effective in reducing pain post SCI.

Intrathecal Clonidine alone does not appear to provide pain relief although it may be helpful in combination with Intrathecal Morphine.

Topical capsaicin reduces post-SCI radicular pain.

Spinal cord stimulation may improve post-SCI neuropathic and musculoskeletal pain.

Dorsal longitudinal T-myelotomy procedures reduce pain post SCI.

DREZ surgical procedure reduces pain post SCI.
Table of Contents

Abbreviations .............................................................................................................................................. i

1.0 Introduction ........................................................................................................................................ 1

2.0 Incidence, Quality and Significance ................................................................................................. 1

2.1 Incidence of Pain Post SCI ................................................................................................................. 1

2.2 Impact on Quality of Life .................................................................................................................... 1

2.3 Severe Pain and SCI Location .......................................................................................................... 2

2.4 Natural History of SCI Pain .............................................................................................................. 2

3.0 Location and Quality of SCI Pain .................................................................................................... 2

4.0 Classification of SCI Pain .................................................................................................................. 3

5.0 Musculoskeletal or Mechanical Pain ............................................................................................... 5

6.0 Central or Neurogenic Dysesthetic Pain .......................................................................................... 5

7.0 Borderzone or Segmental Pain .......................................................................................................... 6

8.0 Psychological Factors ......................................................................................................................... 7

8.1 Catastrophizing and Pain Post SCI .................................................................................................... 8

9.0 Non-Pharmacological Management of Post-SCI Pain .................................................................... 9

9.1 Massage and Heat ............................................................................................................................. 9

9.2 Osteopathy ......................................................................................................................................... 10

9.2 Acupuncture ...................................................................................................................................... 11

9.3 Exercises for Post-SCI Pain ............................................................................................................. 15

9.4 Exercises for Shoulder Pain ............................................................................................................ 16

9.5 Behavioural Management of Pain Post SCI .................................................................................... 19

  9.5.1 Hypnotic Suggestions .................................................................................................................. 19

  9.5.2 Biofeedback ................................................................................................................................ 21

  9.5.3 Cognitive Behavioural Therapy .................................................................................................. 22

  9.5.4 Visual Imagery ............................................................................................................................ 24

9.6 Transcranial Electrical Stimulation Post SCI Pain ........................................................................ 26

9.7 Static Magnetic Field Therapy Post SCI Pain .................................................................................. 29

9.8 Transcutaneous Electrical Nerve Stimulation for Pain Post SCI ................................................ 30

9.9 Transcranial Magnetic Stimulation ............................................................................................... 31

10.0 Pharmacological Management of Post-SCI Pain ........................................................................ 33

10.1 Pharmacological Measures Overall ............................................................................................ 33

10.2 Anticonvulsants in SCI Pain .......................................................................................................... 34

10.3 Tricyclic Antidepressants in Post-SCI pain ................................................................................. 41

10.4 Anaesthetic Medications ................................................................................................................. 43

10.5 Antispasticity Medications ............................................................................................................. 47

This review has been prepared based on the scientific and professional information available in 2013. The SCIRE information (print, CD or web site www.scireproject.com) is provided for informational and educational purposes only. If you have or suspect you have a health problem, you should consult your health care provider. The SCIRE editors, contributors and supporting partners shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of this material.


www.scireproject.com
Abbreviations

AISA  ASIA Impairment Scale
BCM  Broad Compression Massage
BDI  Beck Depression Inventory
BPI  Brief Pain Inventory
BTX  Botulinum Toxin
CBT  Cognitive Behavioural Therapy
CDP  Central Dysesthetic Pain
CESD-SF  Center of Epidemiologic Studies Depression Scale-Short Form
CRT  Circuit Resistance Training
CSQ  Coping Strategies Questionnaire
DAAC  Duration-adjusted average change
DREZ  Dorsal Root Entry Zone
EEG  Electroencephalography
EMG  Electromyography
FIM  Functional Independence Measure
GABA  Gamma-Aminobutyric Acid
GAD  Gabapentin Amitriptyline Diphenhydramime
HADS  Hospital Anxiety and Depression Scale
ISCIP  International Spinal Cord Injury Pain
ITB  Intrathecal Baclofen
LCT  Light Contact Touch
MMPI  Minnesota Multiphasic Personality Inventory
MPI  Multidimensional Pain Inventory
MPQ  McGill Pain Questionnaire
NMDA  N-methyl D Aspartate
NRS  Numeric Rating Scale
NSAIDS  Non-steroidal Anti-inflammatory Drugs
PAD  Zung Pain and Distress
PC  Performance Corrected
PGIC  Patient Global Impression of Change
PM  Pain Medications
PMP  Pain Management Program
PQOL  Perceived Quality of Life
PSS  Perceived Stress Scale
QI  Energy Flow
QOL  Quality of Life
ROM  Range of Motion
RPE  Rating of Perceived Exertion
SCI  Spinal Cord Injury
SF-36  Short Form-36
SF-MPQ  Short Form- McGill Pain Questionnaire
SHCS  Stanford Hypnotic Clinical Scale
SPI  Sternbach Pain Intensity
SRQ  Shoulder Rating Questionnaire
STAI  State Trait Anxiety Inventory
TCA  Tricyclic Antidepressants
TCES  Transcranial Electrical Stimulation
TDCS  Transcranial Direct Current Stimulation
TENS  Transcutaneous Electrical Nerve Stimulation
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>delta-9-tetra hydrocannabinol</td>
</tr>
<tr>
<td>TMS</td>
<td>Transcranial Magnetic Stimulation</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual Analogue Scale</td>
</tr>
<tr>
<td>VNS</td>
<td>Verbal Numeric Scale</td>
</tr>
<tr>
<td>WHYMPI</td>
<td>West Haven Yale Multidimensional Pain Inventory</td>
</tr>
<tr>
<td>WUFA</td>
<td>Wheelchair Users Functional Assessment</td>
</tr>
<tr>
<td>WUSPI</td>
<td>Wheelchair Users Shoulder Pain Index</td>
</tr>
</tbody>
</table>
1.0 Introduction

The last few decades have witnessed increasing sophistication and advances in the rehabilitation of spinal cord injured (SCI) patients with marked improvements in the quality of care accompanied by significant reductions in morbidity and mortality. Despite these impressive gains in bladder, skin, cardiovascular and respiratory care, the treatment of chronic pain in SCI has proven largely refractory to medical management. This lack of treatment efficacy has been complicated by an incomplete understanding of pain in individuals with spinal cord injuries and lack of a standardized framework upon which to classify these injuries (Burchiel & Hsu 2001).

2.0 Incidence, Quality and Significance

2.1 Incidence of Pain Post SCI

Pain is a frequent complication of traumatic spinal cord injury. Reported estimates of the incidence of pain following SCI range anywhere from 11 to 94% (Botterell et al. 1953; Burke 1973; Davidoff et al. 1987; Davis & Martin 1947; Donovan et al. 1982; Kaplan et al. 1962; Kennedy 1946; Munro 1948, 1950; Nashold & Bullitt 1981) with more recent studies reporting an incidence from 48-94% (Britell & Mariano 1991; Cairns et al. 1996; Cohen et al. 1988; Mariano 1992; Rose et al. 1988). Estimates of debilitating or disabling pain range from 11-34% (Botterell et al. 1953; Davis & Martin 1947; Kaplan et al. 1962; Munro 1948; Nepomunceno et al. 1979). Bonica (1991) noted that on combining the data on six reported studies of pain in SCI and 1,028 subjects (Botterell et al. 1953; Burke 1973; Davis & Martin 1947; Nepomunceno et al. 1979; Rose et al. 1988; Woolsey 1986), 53% had various types of “deafferent” pain. These wide ranging estimates are felt to be a reflection of significant heterogeneity in defining pain in this population.

Bonica (1991) reviewed data contained in 10 reports that surveyed 2,449 SCI patients (Botterell et al. 1953; Britell 1986; Burke 1973; Davis & Martin 1947; Kaplan et al. 1962; Munro 1950; Nepomunceno et al. 1979; Richards et al. 1980; Rose et al. 1988; Woolsey 1986). Chronic pain was present in 1,695 (69%) and in 30% of these patients it was rated as severe. Six of the reports (Botterell et al. 1953; Burke 1973; Davis & Martin 1947; Nepomunceno et al. 1979; Rose et al. 1988; Woolsey 1986) analyzed the different types of pain. Out of a total of 1,965 patients, 608 (31%) of the patients had central pain, dysesthesia, or phantom limb pain, 219 (12%) had root pain, and 198 (10%) had visceral pain caused by a central mechanism. There were 1,028 (53%) SCI patients with deafferented pain.

2.2 Impact on Quality of Life

It is estimated that 30-40% of patients with SCI experience severe disabling pain (Burke & Woodward 1976). Pain is often reported as the most important factor for decreased quality of life. Nepomuceno et al. (1979) noted that 23% of individuals with cervical or high thoracic SCI and 37% of those with low thoracic or lumbosacral injury would trade the loss of sexual and/or bowel and bladder function as well as theoretical possibility for cure to obtain pain relief.

Rose et al. (1988) sent a questionnaire to 1,091 spinal cord injured individuals. “Suitable” replies were received from 885 subjects with a total of 615 reporting pain at or below the level of the injury. In 110 subjects this occurred in a nerve root distribution with the remainder below the neurological level of SCI. Pain, which was reported as constant in 43%, was considered severe at some point in the day in half the sample and mild to moderate in 21% of respondents. Prior to
the SCI, 595 of the sample were employed; afterwards only 325 were employed. Interestingly 98 SCI individuals (11%) reported it was the severity of their pain and not their paralysis, which stopped them from working. Of the 325 SCI subjects (83%) who were employed, 269 reported that the pain interfered with their work. A total of 118 SCI subjects found that the pain was severe enough to stop social activity. Pain appeared to be more severe in the evening and at night, interfering with sleep in 325 of respondents (37%). This study clearly pointed out the importance of chronic pain in determining disability and morbidity in SCI patients (Rose et al 1988).

2.3 Severe Pain and SCI Location

Persons with SCI who complain of severe pain are more likely to have low spinal cord or cauda equina lesions (Botterell et al. 1953; Davis & Martin 1947; Nepomuceno et al. 1979; Ragnarsson 1997). Severe pain was noted in 10-15% of persons with quadriplegia; 25% of those with thoracic paraplegia and 42-51% of those with lesions of the cauda equina (Ragnarsson 1997)

2.4 Natural History of SCI Pain

Turner et al. (2001) examined the timing of the development of pain post-SCI noted that in 901 patients with SCI, pain started immediately after SCI in 34%, within the first year in 58%, pain increased over time in 47% and decreased over time in 7%. Turner et al. (2001) noted that pain most often started within the first 6 months following SCI. This has also been noted in several other studies (Nepomuceno et al. 1979; Siddall et al. 1999; Stormer et al. 1997; Turner & Cardenas 1999).

Conclusion

For many SCI patients, pain has a significant impact on quality of life.

Over 50% of SCI patients develop chronic pain. Severe pain is more common the lower down the lesion in the spinal cord. Pain post SCI most often begins within the first 6-12 months post-SCI.

Post-SCI pain is common and often severe beginning relatively early post-injury.

3.0 Location and Quality of SCI Pain

Widerstrom-Noga et al. (2001) conducted a careful analysis of the relationship between the location of the pain and the patients’ description of the pain. In this study 217 of 330 patients reporting chronic pain in a previous survey agreed to participate in the study. Participants had been injured for an average of 8.2±5.1 years and 55.4% were quadriplegic. Most subjects in this study marked multiple areas on a pain drawing with the back area being most frequently implicated (61.8%). 59.9% complained of a burning pain while 54.9% described an aching pain. Interestingly burning pain was significantly associated with pain localized to the front of the torso and genitals, buttocks and lower extremities. In contrast, aching type pain was significantly associated with pain localized to the neck, shoulders and back.
Widerstrom-Noga et al. (2001) noted that the descriptor “burning” is often associated with neuropathic pain (Fenollosa et al. 1993; Ragnarsson 1997; Siddall et al. 1999) whereas “aching” is often associated with musculoskeletal pain (Siddall et al. 1999; Tunks 1986). However, since there is a significant overlap in the quality of pain types it is difficult to establish a definitive clinical relationship (Bowsher 1996; Eide 1998; Widerstrom-Noga et al. 2001). Widerstrom-Noga et al. (2001) suggest that musculoskeletal-type pain (best characterized by the aching pain in the neck, shoulders and back) is potentially amenable to therapeutic interventions and aggressive attempts should be made to ameliorate this type of pain. All of this underscores the need for a reproducible classification system of the pain experienced following SCI. Bennett et al. (2007) have noted that the increasing reliance on validated screening tools may help “form the basis of forthcoming clinical diagnostic criteria”.

**Conclusion**

*The most common types of pain post SCI are: 1) a burning pain (likely neuropathic) usually localized to the front of torso, buttock or legs or 2) an aching pain (likely musculoskeletal) usually localized to the neck, shoulders and back.*

**4.0 Classification of SCI Pain**

Siddall et al. (1997) noted that one of the concerns regarding SCI-related pain was a lack of consensus over a classification system for SCI pain. This has led to considerable variation in incidence and prevalence rates for pain post SCI depending on the classification system used. Twenty-eight classification schemes have been published between 1947 and 2000. A Task Force on Pain Following Spinal Cord Injury of the International Association for the Study of Pain has introduced a taxonomy, which classified SCI pain based on presumed etiology (Burchiel & Hsu 2001; Siddall et al. 2000). Recently, an international group of clinicians and researchers developed a consensus for an SCI pain classification, International Spinal Cord Injury Pain Classification (ISCIP Classification). The overall structure of the ISCIP classification is similar to that developed by the previous IASP classification of pain related to SCI. However, the new system has merged and improved on previously published SCI classification systems. The ISCIP classification incorporates common pain pathology after SCI even those not necessarily related to SCI itself (Bryce et al. 2012).

**Table 1 International Spinal Cord Injury Pain Classification (Bryce et al. 2012)**

<table>
<thead>
<tr>
<th>Tier 1: Pain type</th>
<th>Tier 2: Pain subtype</th>
<th>Tier 3: Primary pain source and/or pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nociceptive</td>
<td>Musculoskeletal</td>
<td>e.g. glenohumeral arthritis, lateral epicondylitis, comminuted femur fracture, quadratus lumborum muscle spasm.</td>
</tr>
<tr>
<td></td>
<td>Visceral</td>
<td>e.g. myocardial infarction, abdominal pain due to bowel impaction, cholecystitis.</td>
</tr>
<tr>
<td></td>
<td>Other nociceptive pain</td>
<td>e.g. autonomic dysreflexia headache, migraine headache, surgical skin incision.</td>
</tr>
<tr>
<td>Neuropathic</td>
<td>At Level SCI pain</td>
<td>e.g. spinal cord compression, nerve root compression, cauda equine compression</td>
</tr>
<tr>
<td></td>
<td>Below level pain</td>
<td>e.g. spinal cord ischemia, spinal cord compression</td>
</tr>
<tr>
<td></td>
<td>Other neuropathic pain</td>
<td>e.g. carpal tunnel syndrome, trigeminal neuralgia, diabetic polyneuropathy.</td>
</tr>
<tr>
<td>Other pain</td>
<td></td>
<td>e.g. fibromyalgia, Complex Regional Pain Syndrome</td>
</tr>
<tr>
<td>Tier 1: Pain type</td>
<td>Tier 2: Pain subtype</td>
<td>Tier 3: Primary pain source and/or pathology</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Unknown pain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Previous IASP Classification of Pain Related to SCI (Burchiel & Hsu 2001)

<table>
<thead>
<tr>
<th>Broad Type (Tier 1)</th>
<th>Broad System (Tier 2)</th>
<th>Specific Structure/Pathology (Tier 3)</th>
</tr>
</thead>
</table>
| **Nociceptive**     | Musculoskeletal        | Bone, joint, muscle trauma, or inflammation  
                        |                                     | Mechanical instability  
                        |                                     | Muscle spasm  
                        |                                     | Secondary overuse syndromes  
|                     | Visceral               | Renal calculus, bowel, sphincter dysfunction, etc.  
                        |                                     | Dysreflexic headache  |
|                     | Above Level            | Compressive mononeuropathies  
                        |                                     | Complex regional pain syndromes  
| **Neuropathic**     | At Level               | Nerve root compression (including cauda equine)  
                        |                                     | Syringomyelia  
                        |                                     | Spinal cord trauma/ischemia (transitional zone, etc.)  
                        |                                     | Dual-level cord and root trauma (double lesion syndrome)  |
|                     | Below Level            | Spinal cord trauma/ischemia (central dysesthesia syndrome, etc.)  |

Table 3 SCI pain types according to major classification*

<table>
<thead>
<tr>
<th>Bryce/Ragnarsso n</th>
<th>Cardenas</th>
<th>Donovan</th>
<th>ISAP</th>
<th>Tunks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above level</td>
<td>Neurologic</td>
<td>1) Segmental</td>
<td>Nociceptive</td>
<td>Above level</td>
</tr>
<tr>
<td>1) Nociceptive</td>
<td>1) Spinal cord</td>
<td>2) Spinal cord</td>
<td>1) Musculoskeletal</td>
<td>1) Myofascial</td>
</tr>
<tr>
<td>2) Neuropathic</td>
<td>2) Transition zone</td>
<td>3) Visceral</td>
<td>2) Visceral</td>
<td>2) Syringomyelia</td>
</tr>
<tr>
<td>At level</td>
<td>3) Radicular</td>
<td>4) Mechanical</td>
<td>3) Above level</td>
<td>3) Non-spinal cord injury</td>
</tr>
<tr>
<td>3) Nociceptive</td>
<td>4) Visceral</td>
<td>5) Psychogenic</td>
<td>4) At level</td>
<td>4) Radicular</td>
</tr>
<tr>
<td>4) Neuropathic</td>
<td>5) Musculoskeletal</td>
<td></td>
<td>5) Below level</td>
<td>5) Hyperalgesic border reaction</td>
</tr>
<tr>
<td>Below level</td>
<td>6) Mechanical spine</td>
<td></td>
<td></td>
<td>6) Fracture</td>
</tr>
<tr>
<td>5) Nociceptive</td>
<td>6) Overuse</td>
<td></td>
<td></td>
<td>7) Myofascial (incomplete)</td>
</tr>
<tr>
<td>6) Neuropathic</td>
<td></td>
<td></td>
<td></td>
<td>Below level</td>
</tr>
</tbody>
</table>

*This article was published in Physical Medicine and Rehabilitation Clinics of North America, 18, Ullrich, Pain Following Spinal Cord Injury, 217-233, Copyright Elsevier (2007).

Table 4 Reliability of SCI pain classification systems

<table>
<thead>
<tr>
<th>Classification</th>
<th>Kappa coefficient</th>
<th>Percent agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryce and colleagues</td>
<td>.70</td>
<td>Unavailable</td>
</tr>
<tr>
<td>Cardenas</td>
<td>.68</td>
<td>Unavailable</td>
</tr>
<tr>
<td>Donovan</td>
<td>.55</td>
<td>50%-62%</td>
</tr>
<tr>
<td>IASP</td>
<td>.49</td>
<td>52%</td>
</tr>
<tr>
<td>Tunks</td>
<td>.49</td>
<td>27%</td>
</tr>
</tbody>
</table>

*Kappa coefficient is the proportion of agreement controlling for chance agreement, with 1.0 representing perfect agreement between raters. Kappa coefficients greater than .60 or .70 reflect substantial interrater agreement.*
5.0 Musculoskeletal or Mechanical Pain

Musculoskeletal or mechanical pain occurs at or above the level of the lesion and is due to changes in bone, tendons or joints (Guttmann 1973). This is referred to as nociceptive pain caused by a variety of noxious stimuli to normally innervated parts of the body (Ragnarsson 1997). Overuse of remaining functional muscles after spinal cord injury or those recruited for unaccustomed activity may be of primary importance in some patients (Farkash & Portenoy 1986). Pain may also be secondary to spinal osteoporosis or facet arthropathy (Farkash & Portenoy 1986). Instability of the vertebral column may also be a problem (Farkash & Portenoy 1986). Pain is usually dull and aching in character and although more common soon after SCI, it may become chronic.

Sie et al. (1992) studied 239 SCI outpatients for the presence of upper extremity pain. Of the 136 patients with quadriplegia, 55% reported upper extremity pain, most commonly at the shoulder (46% of all subjects). In the case of shoulder pain, 45% were orthopedic-related including tendonitis, bursitis, capsulitis and osteoarthritis. Of the 103 paraplegics, 66 reported upper extremity pain with two-thirds reporting symptoms of carpal tunnel syndrome and 13 reporting musculoskeletal-related shoulder pain. Dalyan et al. (1999), in a questionnaire returned by 130 SCI patients, found that 58.5% of patients reported upper extremity pain. Of these, 71% had shoulder pain, 53% wrist pain, 43% hand pain, and 35% elbow pain. Pain was most likely to be associated with pressure relief, transfers, and wheelchair mobility. Subbarao et al. (1995), in a survey of 800 SCI patients, found that 72.7% of responders reported some degree of chronic pain at the wrist and shoulder, with wheelchair propulsion and transfers being responsible for most of the pain. McCasland et al. (2006) noted that in their survey, 70% of SCI had shoulder pain, one-third had a previous injury to their shoulder and 52% reported a bilateral pain. Quadriplegics were more likely to have shoulder pain (80%). Previous shoulder trauma increased the risk of having shoulder pain.

6.0 Central or Neurogenic Dysesthetic Pain

"Central" dysesthesia or "deafferentation" pain is the most common type of pain experienced below the level of SCI and is generally characterized as a burning, aching and/or tingling sensation. In many cases this dysesthetic or deafferentation pain has defied a pathophysiological explanation (Britell 1991) although most researchers firmly support a central nervous system origin for this pain. Nashold (1991) goes as far as stating that except for radicular pain, all other pains of paraplegia are central or deafferentation in origin. This pain is most often perceived in a generalized manner below the level of the lesion, often a diffuse burning type of pain (Britell 1991; Tunks 1986). Burning pain is reportedly most common with lesions at the lumbar levels, although it may be found with SCI at thoracic and cervical levels (Tunks 1986). Nashold (1991) reported this pain occurred almost immediately after SCI and persisted.

Beric (1997) refers to this pain as central dysesthetic pain (CDP) and found dissociative sensory loss and absence of spinothalamic-anteralateral functions, with different degrees of dorsal column function preservation present almost exclusively in incomplete SCI patients. CDP takes weeks or months to appear and is often associated with recovery of some spinal cord function. Paradoxically CDP is often characterized by complete loss of temperature, pinprick, and pain perception below the level of the lesion. It rarely occurs in spinal cord Injuries with complete sensory loss or loss of both sensory and motor functions below the level of the lesion. Davidoff et al. (1987a) concurred and further noted dysesthetic pain was more likely to be found in
incomplete paraplegia resulting from penetrating wounds of the spinal cord, and in spinal fractures treated with conservative management.

A number of factors may contribute to exacerbations of these "central" pain syndromes; these include visceral diseases or disturbances, movement, smoking or alcohol, emotional factors, fatigue, and even weather changes (Botterell et al. 1953; Davis & Martin 1947; Davis 1975; Tunks 1986). Pressure sores, particularly if infected, or an occult injury such as a fracture, may result in an increase in burning, dysesthetic pain. These stimuli often provoke autonomic dysreflexic-like symptoms and simultaneously also may aggravate this "burning" pain.

7.0 Borderzone or Segmental Pain

Individuals with SCI frequently experience a band of pain and hyperalgesia at the border zone between diminished or abnormal and preserved sensation (Botterell et al. 1953; Davis 1975; Heliporn 1978; Kaplan et al. 1962; Maury 1978; Melzack & Loeser 1978; Michaelis 1970; Tunks 1986). In the more recent literature, this segmental pain is further described as occurring at or just above the level of sensory loss in the cutaneous transition zone from the area of impaired/lost sensation to areas of normal sensation, involving at least one to three dermatomes (Friedman & Rosenblum 1989; Nashold 1991; Ragnarsson 1997) and is often associated with spontaneous painful tingling or burning sensations in the same area. Ragnarsson (1997) also noted that in an individual with a cervical cord injury, segmental pain may be described as tingling, burning or numbing pain in the shoulders, arms or hands, those with a thoracic cord injury frequently describe a circumferential, feeling of tightness and pain around the chest and abdomen while lumbar lesions tend to be localized to the groins and different parts of the lower extremities. According to Nashold (1991) paraplegics often complain that touching the skin in the pain region activates the pain causing it to radiate into the lower parts of the body, especially the legs. Pain can be triggered by stroking and/or touching the skin in adjacent painful dermatomes (Nashold 1991). Even light touch or the pressure of clothing or bed sheets over this region may provoke marked discomfort (Tunks 1986). It may be accompanied by sweating or vasodilation at or below the level of hyperalgesia. Segmental pain is generally symmetrical although a partial spinal cord injury with asymmetrical neurological involvement will produce asymmetries (Nashold 1991).

This pain has also been described as "neuropathic at level pain" (Siddall et al. 1997) Although several theories have been proposed (Levitt 1983; Matthew & Osterholm 1972; Melzack & Loeser 1978; Nashold & Bullitt 1981; Pollock et al. 1951; Tunks 1986) the neurological mechanism responsible for this area of hyperalgesia after spinal injury is not well understood (Farkash & Portenoy 1986). Although radicular pain is most severe in incomplete SCI lesions, it is also seen in transected cauda equina lesions which are by definition radicular types of pain (Heaton & Coates 1965; Siddall et al. 1997). It may also be secondary to spinal cord instability by facet or disc material, or to direct damage to the nerve root during the initial injury (Burke 1973; Nashold 1991). This "radicular" pain is associated with sensory change in the involved painful dermatome (Nashold 1991) and is most common to cervical or lumbosacral nerve roots. Non-neural structures, such as the dura mater, have also been suggested as a source of radicular pain (Cyriax 1969; Farkash & Portenoy 1986). In addition, it has been suggested that central borderzone pain may be generated in the damaged spinal cord just proximal to the spinal cord injury (Nashold 1991; Pollock et al. 1951). Unfortunately, unless there is definitive evidence on imaging of nerve root damage, it is difficult to distinguish between these various mechanisms of pain.
To reflect this uncertainty Siddall et al. (1997) in their proposed classification of SCI pain note that this "neuropathic at level pain" is divided into radicular and central pain. Radicular pain is due to nerve root pathology while central pain is due to changes within the spinal cord or possibly supraspinal structures. Pain attributable to nerve root damage is suggested by features of neuropathic pain (i.e. burning, stabbing, shooting, electric-like pain, allodynia) and increased pain with spinal movement. Sjolund (2002) notes that this pain is thought to occur from nerve root entrapment and may occasionally benefit from decompression.

However, pain, which appears radicular in nature, may occur in the absence of nerve root damage. This leads to the second grouping of borderzone pain, namely central pain or that which is due to pathology within the spinal cord thought to be the result of damage to the gray matter of the dorsal horn of the spinal cord (Ragnassaron 1997; Woolsey 1995). According to Ragnassaron (1997), such an injury "has been said to result in hyperactivity of the nociceptor cells within the dorsal horn (Nashold & Bullitt 1981; Nashold & Ostdahl 1979) which can be electrically recorded (Nashold & Alexander 1989)." Sjolund (2002) notes that this second type of at level neuropathic pain is experienced as a girdle pain uni- or bilaterally in 2-4 segments of the transitional region. This pain is described as stimulus independent, often accompanied by troublesome allodynia or hyperalgesia and thought to arise from segmental deafferentation (Sjolund 2002).

8.0 Psychological Factors

Most studies of chronic SCI pain have focused on the medical causes and clinical manifestations of pain while much less is understood about how psychosocial factors impact SCI pain (Summers et al. 1991). Pain itself was found to be associated with greater emotional distress than the SCI itself. A negative psychosocial environment along with increased age, depression, anxiety and intellect were found to be associated with reports of greater post-SCI pain severity interfering with activities of daily living (Richards et al. 1980). Greater pain severity was not associated with physiological factors such as injury level, completeness of injury, surgical fusion and/or instrumentation or veteran status. The authors were unable to distinguish whether the psychological factors were a consequence of, or contributors to, greater pain severity. Summers et al. (1991) studied 54 SCI patients (19 with quadriplegia and 35 with paraplegia) and of these, 42 patients assessed with the Pain questionnaire found that anger and negative cognitions were associated with greater pain severity. Severity of pain was higher in patients who reported pain in response to a question on general well-being, those that were less accepting of their disability and those that perceived that a significant other would express punishing responses to their pain behaviours. The authors concluded that the experience of pain was associated with psychosocial factors. Hence treatment of post-SCI pain should involve these multidimensional aspects.

Cohen et al. (1988) found that patients with complete SCIs reported significantly less severe pain than did pain clinic patients. However, they did not differ from patients with incomplete lesions. Patients with complete SCIs and pain clinic patients showed a significantly more disturbed Minnesota Multiphasic Personality Inventory (MMPI) profile than did patients with incomplete SCIs. It was hypothesized that those patients with complete lesions view themselves as more functionally limited than patients with incomplete lesions, and the completeness of the SCI may be more important in determining psychosocial adjustment than pain per se. Rintala et al. (1998) in community-based men with SCI found that chronic pain was associated with more depressive symptoms, more perceived stress and poorer self-assessed health.
Wollaars et al. (2007) administered questionnaires to persons with a SCI. Of the potential 575 subjects, 49% provided responses. SCI pain prevalence was 77%. Factors associated with less pain intensity included more internal pain control and coping, less catastrophizing, a higher level of lesion and a non-traumatic SCI cause. More pain was associated with greater pain-related disability. Lower catastrophizing was related to better health. Factors related to greater well-being included less helplessness and catastrophizing, greater SCI acceptance and lower anger levels. Greater levels of depression were associated with higher levels of SCI helplessness, catastrophizing and anger. The authors noted that chronic SCI pain and quality of life were both largely associated with several psychological factors of which pain catastrophizing and SCI helplessness were more important. Surprisingly, pain intensity showed no independent relationships with health, well-being and depression (Wollaars et al. 2007).

Widerström-Noga et al. (2007) studied 190 patients with SCI and chronic pain and were able to identify 3 subgroups. The first group was described as 'dysfunctional', characterized by higher pain severity, life interference, affective distress scores, and lower levels of life control and activities scores. The second group was described as ‘interpersonally supported’, characterized by moderately high pain severity, and higher life control, support from significant other, distracting responses, solicitous response, and activities scores. The final group was described as 'adaptive copers', characterized by lower pain severity, life interference, affective distress, support from significant others, distracting responses, solicitous responses, activities and higher life control scores. Compared with dysfunctional subgroup, the interpersonally supported group reported significantly greater social support (Widerström-Noga et al. 2007).

8.1 Catastrophizing and Pain Post SCI

When pain post SCI is refractory to pharmacological and surgical treatment, it is important to fully understand the negative impact of the patient’s psychosocial environment prior to undertaking more invasive approaches to treatment.

Table 5 Catastrophizing and Pain Post SCI

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giardino et al. 2003</td>
<td>USA</td>
<td>Case Series</td>
<td>N=74</td>
<td>Population: Age=21-64 yr; Gender: males=60, females=13.</td>
<td>Treatment: Questionnaire.</td>
<td>Outcome Measures: Coping Strategies Questionnaire (CSQ), Short form McGill Pain Questionnaire (SF-MPQ), West Haven-Yale Multidimensional Pain Inventory (WHYMPI) solicitous subscale and CES-D scale.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. CSQ catastrophizing was associated with WHYMPI (p&lt;0.05), CES-D (p&lt;0.001), SF-MPQ (sensory pain) (p&lt;0.01) and CSQ SF-MPQ (affective pain) (p&lt;0.001).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Catastrophizing also accounted for significant variance in sensory pain scores (t=2.63, p&lt;0.05). An interaction between relationship type and catastrophizing was also found (p&lt;0.05).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. A significant relationship was noted between affective pain score and solicitousness (p&lt;0.05) and catastrophizing and solicitousness (p&lt;0.05).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4. Catastrophizing itself accounted for a significant amount of variance in affective pain scores (p&lt;0.01).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Giardino et al. (2003) noted that pain-related catastrophizing, or exaggerating the negative consequences of a situation, has been associated with greater pain intensity, emotional distress and functional disability in patients with chronic pain conditions and SCI. This was thought to provide partial support for a “communal coping” model of catastrophizing, where catastrophizing in persons with pain may function as a social communication directed toward obtaining social proximity, support or assistance.

**9.0 Non-Pharmacological Management of Post-SCI Pain**

Before moving to pharmacological and surgical interventions, it is important to deal with those factors which may intensify or worsen the experience of pain. As mentioned previously, SCI pain may be worsened by decubitus ulcers, a urinary tract infection or stone, autonomic dysreflexia, increased spasticity, anxiety, depression, psychosocial factors and other contributors to post-SCI pain (Davis et al. 1998; Tunks 1986). There are a number of non-pharmacological interventions for post-SCI pain which have been studied from massage to hypnosis.

**9.1 Massage and Heat**

Massage and heat are used primarily to treat musculoskeletal pain. Their benefit is well known in a number of musculoskeletal pain disorders, although there are significant differences among therapists as to how treatment is delivered.

Table 6 Massage and Heat in Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chase et al. 2013</td>
<td>USA</td>
<td>PEDro=5</td>
<td>RCT</td>
<td>N=40</td>
<td><strong>Population:</strong> Age=40.24 yr. Sex: Males=33, Females=7; Mean time since injury was 69.35days. Severity of injury: complete=23. Incomplete=17. Type of pain=Neuropathic and musculoskeletal pain. <strong>Intervention:</strong> SCI individuals in rehabilitation facility were randomly assigned to receive broad compression massage (BCM) or light contact touch (LCT) 3 times a week for 2 weeks and then crossed over to the alternative treatment after a 1 week wash-out period. <strong>Outcome Measures:</strong> Brief Pain Inventory (BPI); PHQ9</td>
<td>1. Pain intensity reduced significantly more in the individuals receiving LCT first compared to the BCM group, p=0.01. 2. No significant difference between the groups was seen in PHQ9.</td>
</tr>
<tr>
<td>Norrbrink &amp; Lundeberg 2011</td>
<td>Sweden</td>
<td>Prospective Controlled Trial</td>
<td>N=30</td>
<td><strong>Population:</strong> Age=47.1 yr. Mean time since injury was 11.9 yr. Type of pain=Neuropathic pain. <strong>Intervention:</strong> Participants were placed in one of two groups to receive acupuncture or massage therapy. Both groups consisted of 6 weeks with treatment twice a week. <strong>Outcome Measures:</strong> Visual Analogue Scale</td>
<td>1. Worst pain intensity and pain unpleasantness improved significantly in the acupuncture group compared to the massage group. 2. However, no significant differences were seen in pain intensity between the two groups.</td>
<td></td>
</tr>
<tr>
<td>Norrbrink-Budh &amp; Lundeberg 2004</td>
<td>Sweden</td>
<td>Case Series</td>
<td>Initial N=402; Final</td>
<td><strong>Population:</strong> Age=7-83 yr; Gender: males=44, females=46; Time since injury=14.4 yr. Type of pain=Neuropathic and musculoskeletal pain. <strong>Treatment:</strong> No treatment questionnaire.</td>
<td>1. The authors noted that massage and heat appeared to be the best non-pharmacological treatments.</td>
<td></td>
</tr>
</tbody>
</table>
It stands to reason that local heat and massage therapy would be most effective for musculoskeletal pain post-SCI. Norrbrink Budh and Lundeberg (2004) in a survey of SCI patients 3 years post-injury found massage and heat were the best non-pharmacological treatments. In a prospective controlled trial, 30 individuals were divided into either a massage therapy or acupuncture group. Each group received treatment two times a week for 6 weeks and were followed up for 2 months. The study found that the massage therapy group was not effective in improving pain intensity compared to the acupuncture group. In a crossover RCT, Chase et al. (2013) found that patients that received light touch and then massage were more likely report reduction in pain intensity than those that received massage and then light touch. The study did not examine the effectiveness of either treatment compared to the alternative; hence, it is difficult to examine if one treatment itself is more effective than the other.

**Conclusion**

There is level 2 evidence (from one randomized controlled trial and one prospective controlled trial; Chase et al. 2012; Norrbrink & Lundeberg 2011) that massage therapy may not improve neuropathic and musculoskeletal pain intensity post SCI.

Massage may not be helpful for post-SCI neuropathic and musculoskeletal pain.

### 9.2 Osteopathy

Osteopathy treatment has been shown to be effective in the relief of chronic pain in individuals with osteoarthritis and inflammatory conditions. Osteopathy’s effect on pain is related to its influence on the release of beta-endorphin and reduction in serotonin (Degenhardt et al. 2007).

**Table 7 Osteopathy in Post-SCI Pain**

<table>
<thead>
<tr>
<th>Author Year Country Score Research Design Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arienti et al. 2011 Italy PEDro=6 RCT N=47</td>
<td><strong>Population:</strong> Severity of injury: AIS A=33, B, C and D=14; Level of injury: paraplegia=19, tetraplegia=7. <strong>Type of pain:</strong> Neuropathic</td>
<td>1. Rates of improvement based on the VNS scores were similar across the two treatments ($p=0.26$). 2. The highest pain relief was seen in the combined pharmacological and osteopathic group compared to the pharmacological alone ($p=0.05$) and the osteopathic alone ($p=0.001$).</td>
</tr>
</tbody>
</table>
Arienti et al. (2011) examined the use of osteopathic treatment in reducing neuropathic pain post SCI. Participants were randomized into one of three groups: the pharmacological group received 600 mg of pregabalin per day; the combined pharmacological and osteopathy group received osteopathic treatment once a week for the first month, once every fortnight for the second month and once during the third month for 45 minutes along with the pharmacological treatment; the osteopathic group received only the osteopathic treatment schedule described and the combined group received both active treatments. The study found verbal numeric scale (VNS) ratings were not significantly different among the groups from baseline to 8 weeks. However, the combined treatment group had the highest pain relief compared to the pharmacological alone (p=0.05) and the osteopathic alone (p=0.001) groups from 13 to 24 weeks.

Conclusion

There is level 1b evidence (from one randomized controlled trial; Arienti et al. 2011) that osteopathy alone is not effective in improving neuropathic pain post SCI.

Osteopathy alone may not be helpful for post-SCI neuropathic pain.

9.2 Acupuncture

Acupuncture is a component of traditional Chinese medicine that has been used for the treatment of pain for thousands of years and is based on the premise that illness arises from the imbalance of energy flow (Qi) through the body (Dyson-Hudson et al. 2001). Needle acupuncture involves inserting fine needles into specific points to correct these imbalances (Dyson-Hudson et al. 2001; NIH Consensus Conference 1998; Pomeran 1998; Wong & Rapson 1999). Acupuncture has been shown to activate type II and type III muscle afferent nerves or A delta fibers, blocking the pain gate by stimulating large sensory neurons as well as releasing endogenous opioids, neurotransmitters and neurohormones (Dyson-Hudson et al. 2001; Pomeran 1998; Wong & Rapson 1999).

Table 8 Acupuncture in Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyson-Hudson et al.</td>
<td>Population: Mean age=39.9 yr; Gender:</td>
<td>1. Both groups experienced significant...</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Year Country</td>
<td>PEDro Score Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yeh et al. 2010 Taiwan</td>
<td>PEDro=6 RCT</td>
<td>N=99</td>
<td>Population: Age=60.4 yr. Treatment: Patients who previously underwent surgery for non-traumatic SCI were randomized to 3 groups: 1) received true acupoint intervention through electrical stimulation; 2) received sham acupoint; 3) received no acupoint stimulation. Outcome Measures: Visual Analogue Scale (VAS), Brief Pain Inventory (BPI)</td>
<td>1. Significant difference was seen in pain intensity between the true acupoint group and sham group (p&lt;0.03) and the true acupoint group and control group (p&lt;0.02). 1. A significant reduction was also seen in the impact of pain on sleep in the true acupoint group compared to the other two groups (p&lt;0.05).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nayak et al. 2001 USA</td>
<td>Pre-post Initial N=31; Final N=22</td>
<td></td>
<td>Population: Mean age=43.14 yr; Gender: males=15, females=7; Level of injury: C1-L3; Severity of injury: AIS: A, C, D; Time since injury=8.49 yr; Length of pain=8.46 yr. Type of pain=Neuropathic and musculoskeletal Treatment: 15 acupuncture treatments were administered over a 7.5-week period using a specific set of acupuncture points with additional points</td>
<td>2. Pain intensity decreased over time: worst pain (p&lt;0.05), average pain, (p&lt;0.01), and present pain (p&lt;0.01). 3. Post-treatment decline in pain intensity was maintained at 3 mo follow-up (pre-treatment vs. follow-up: p&lt;0.01). 4. A difference in the ratings of pain intensity between pre- and post-treatment (p&lt;0.001) was noted and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyson-Hudson et al. 2001 USA</td>
<td>PEDro=7 RCT</td>
<td>N=24</td>
<td>Population: Age=28-69 yr; Gender: males=18, females=6; Level of injury: paraplegia, tetraplegia; Time since injury=5-33 yr; Length of shoulder pain=4 mo-22 yr. Type of pain=Noiceceptic Treatment: Subjects received either acupuncture treatments (sessions lasted 20-30 min) or Trager Psychophysical Integration (approx. 45 min). Consisted of both table work and mentastic exercises. Outcome Measures: Intake questionnaire (demographics and medical history), Weekly log, Wheelchair User’s Shoulder Pain Index (WUSPI), Numeric rating scale, Verbal rating scale, range of motion.</td>
<td>1. Analysis of treatment on PC-WUSPI scores using ANOVA showed a significant effect of time for both treatments (Acupuncture p&lt;0.001 and Trager p=0.001). 2. Overall a reduction of the PC-WUSPI could be seen when looking at the data from the beginning of treatment to the end for both groups (p&lt;0.05). 3. Looking at the effect of treatment on the numeric rating scores, the ANOVA showed a significant effect of time for both acupuncture and Trager groups for average pain and most severe pain (p&lt;0.01, p&lt;0.001 respectively), for the least severe pain the acupuncture group showed a significant reduction (p&lt;0.01) compared to the Trager group. 4. Verbal response scores-Looking at the effect of treatment on the VRS scores for both groups; there was a statistically significant effect for both groups (p=0.001).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Year Country</td>
<td>PEDro Score Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007 USA PEDro=9 RCT</td>
<td>N=17</td>
<td></td>
<td>males=18, females=5; Level of injury: tetraplegia=8, paraplegia=15; Type of pain: nociceptive musculoskeletal shoulder pain. Treatment: Individuals received 10 treatments, 2x/wk (acupuncture or sham acupuncture) for 5 weeks. Outcome Measures: Wheelchair User’s Shoulder Pain Index (WUSPI), Numeric Rating Scale (NRS)</td>
<td>reduction in shoulder pain (p&lt;0.005), as indicated by WUSPI. 2. Greater reduction in pain in acupuncture group vs. sham acupuncture group (66% vs. 43%) was noted; however there was no statistically significant difference in pain reduction between the two groups on WUSPI. 3. No significant differences in NRS between the two groups, though both had significant pain reduction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Discussion

Dyson-Hudson and colleagues conducted two RCTs (2001; 2007) examining the effect of a 10 treatment, 5 week program of manually stimulated acupuncture on shoulder pain compared to two different control interventions. In the first study, Dyson-Hudson et al. (2001), compared acupuncture treatment to Trager Psychosocial Integration performed by a certified Trager practitioner. Trager therapy is a form of bodywork and movement re-education designed to induce relaxation and encourage the patient to identify and correct painful patterns. It was hypothesized that chronically contracted muscles shortened by stress led to pain (Dyson-Hudson et al. 2001). There was a significant effect over time for both treatments in reducing shoulder pain but there was no difference between the two groups. The second RCT, (Dyson-
Hudson et al. (2007) examined acupuncture against sham acupuncture (i.e. minimal depth needle insertion at nonspecific anatomic sites). The results suggested that acupuncture was no more effective than sham acupuncture for the treatment of shoulder pain post SCI and/or that there may be a significant placebo effect associated with these interventions.

An RCT by Yeh et al. (2010) found that patients that received acupoint electrical stimulation showed significant improvement in pain intensity and average pain compared to those that received sham acupoint electrical stimulation treatment or no treatment (p<0.01). Improvement in impact of pain on sleep was also reported in the acupoint electrical stimulation group compared to the other two groups (p<0.05).

In a prospective controlled trial, participants in the acupuncture group reported significant reduction in worst pain intensity and pain unpleasantness compared to those in the massage group at 2 month follow-up. No significant difference was seen between the two groups on pain intensity based on the Visual Analogue Scale (VAS) (Norrbrink & Lundeberg 2011).

Nayak et al. (2001) administered 15 acupuncture treatments over a 7.5-week period of time. Pain intensity decreased from pre-treatment to post-treatment with post-treatment decline in pain intensity being maintained at 3 month follow-up. Despite these results, 54.5% of those treated reported a worsening of pain after treatment. Those that reported pain below their injury did not respond to treatment (p<0.05). Those who reported pain relief at 3 month follow-up reported only moderate levels of pain intensity at the beginning of the study compared to those who did not report pain relief at follow-up (p<0.01). With the overall reduction in pain intensity there were also a decrease in pain interference with ADLs and an improvement in overall well-being. The authors felt that 50% of patients demonstrated improvement in their pain with acupuncture.

Rapson et al. (2003) asked patients to rate their pain intensity according to a visual analogue scale after electroacupuncture treatments. Sixty-seven percent (24/36) of patients reported improvement, with improvement best for those with bilateral symmetric constant burning pain.

Banerjee (1974) reported on five patients who developed burning, distressing pain below the level of SCI and who responded to transcutaneous electrical nerve stimulation (TENS) strong enough to lead to muscle contraction below the level of injury. The exact mechanism of action for this analgesic response was not delineated.

Conclusion

There is level 1a evidence (from two randomized controlled trials; Dyson-Hudson et al. 2001, 2007) that in general acupuncture is no more effective than Trager therapy or sham acupuncture in reducing nociceptive musculoskeletal shoulder pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Yeh et al. 2010) that acupuncture and electroacupuncture reduces neuropathic pain of patients with SCI.

Acupuncture may reduce post-SCI neuropathic and musculoskeletal pain. Electrostimulation acupuncture is effective in improving neuropathic pain in SCI pain.
9.3 Exercises for Post-SCI Pain

Exercise has been shown to improve subjective well-being for individuals with chronic disease and disability.

Table 9: Exercises for Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ginis et al. 2003</td>
<td>Canada</td>
<td>PEDro=6</td>
<td>RCT</td>
<td>N=34</td>
</tr>
<tr>
<td>Ditor et al. 2003</td>
<td>Canada</td>
<td>Pre-post</td>
<td>RCT</td>
<td>N=7</td>
</tr>
</tbody>
</table>

Population: SCI: Mean age=38.6 yr; Gender: males=23, females=11; Severity of injury: complete=14, incomplete=13. Type of pain=Neuropathic and musculoskeletal

Treatment: Participants in the non-exercise group were asked to continue their usual activities but they were asked not to exercise regularly. Those in the exercise group participated in 5 min of stretching, 15-30 min of aerobic arm ergometry exercise and 45-60 min of resistance exercise. These subjects trained 2x/wk in small groups.

Outcome Measures: Pain perception (two items from the Short form-36 Health Survey), symptom self-efficacy and perceived control (two core items from the Beliefs scale and a modified version of the arthritis belief scale), stress was measured using the perceived stress scale.

1. After 3 mo, changes in potential mediators were seen in:
   - The treatment group showed a significant decrease in stress (p=0.01) and pain (p=0.03) than the control group.
   - The two groups for QoL (p=0.007); satisfaction with physical function (p<0.01), satisfaction with physical appearance (p=0.007); depression (p=0.02).

2. Stress and pain (mediators of QoL):
   - Once baseline pain and stress were controlled for, the 3 mo scores for pain was (R²=0.15, p<0.01) and for stress it was (R²=0.12, p<0.01).
   - These were significant predictors of baseline adjusted 3 mo QoL.

3. Stress and pain as mediators of depression:
   - Changes in pain but not stress explained significant variance in baseline adjusted depression scores (R²=0.19 and 0.04).
   - Adjusted pain scores showed variance in the adjusted 3 mo depression scores (R²=0.19 and <0.01).

Discussion
Ginis et al. (2003) studied SCI patients who underwent a regular exercise program and compared them to SCI patients who did not. Those who underwent the regular exercise program experienced a significant improvement in pain scores which in turn accounted for improved depression scores. Ditor et al. (2003) found that pain scores were negatively correlated with adherence to a later exercise program.

**Conclusion**

*There is level 1b evidence (from one randomized controlled trial; Ginis et al. 2003) that a regular exercise program significantly reduces post-SCI neuropathic and musculoskeletal pain.*

Regular exercise reduces post-SCI neuropathic and musculoskeletal pain.

### 9.4 Exercises for Shoulder Pain

Shoulder pain is a common form of musculoskeletal pain following SCI and is often the result of increased physical demands, awkward or over-use of the upper extremities as the individual with SCI compensates for loss of lower limb functioning (Curtis et al. 1999). Curtis et al. (1999) has noted, “tightness of the anterior shoulder musculature, combined with weakness of the posterior shoulder musculature both seem to contribute to development of shoulder pain in wheelchair users (Burnham et al. 1993; Curtis et al. 1999; Millikan et al. 1991; Powers et al. 1994) and may be further complicated by paralysis and spasticity in the individual with tetraplegia (Powers et al. 1994; Silverskiold & Waters 1991).” The prevalence of shoulder pain in SCI individuals ranges between 30-100% (Curtis et al. 1999) and is a consequence of increased physical demands and overuse (Nichols et al. 1979; Pentland & Twomey 1991, 1994).

**Table 10 Shoulder Pain Management Post SCI**

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curtis et al. 1999</td>
<td>USA</td>
<td>PEDro=5</td>
<td>RCT</td>
<td>N=42</td>
<td>Population: Mean age=35 yr; Gender: males=35, females=7; Level of injury=cervical to lumbar; Duration of wheelchair use=24 yr. Type of pain=Noiciceptive. Treatment: The experimental group attended a 60 min educational session where they were instructed in five shoulder exercises. Outcome Measures: Self-report questionnaire (demographic and medical info), Wheelchair User’s Shoulder Pain Index (WUSPI), and Visual Analogue Scale (VAS) used to rate intensity of pain.</td>
<td>1. When looking at the effect of exercise intervention on performance corrected (PC) WUSPI, a two factor repeated measures ANOVA showed a significant effect of time only (p=0.048). 2. There were no significant differences between control and experimental group in age, years of wheelchair use or activity levels although the control group had much lower pain scores at baseline.</td>
</tr>
<tr>
<td>Author/Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Serra-Ano et al. 2012</td>
<td>Spain</td>
<td>Pre-Post</td>
<td>N=15</td>
<td></td>
<td><strong>Population:</strong> Age=26-70yr; Gender: males=15; Severity of injury=complete. <strong>Treatment:</strong> SCI individuals with chronic shoulder pain participated in an 8 week resistance training program with 3 sessions per week. <strong>Outcome Measures:</strong> Wheelchair User's Shoulder Pain Index (WUSPI)</td>
<td>1. Significant decrease in pain intensity was reported post treatment (p&lt;0.05). 2. Upper limb functionality including rotation, flexion and extension improved significantly post treatment (p&lt;0.05).</td>
</tr>
<tr>
<td>Nawoczenski et al. 2006</td>
<td>USA</td>
<td>Prospective Controlled Trial</td>
<td>N=41</td>
<td></td>
<td><strong>Population:</strong> Exercise group: Mean age=47.1 yr; Gender: males=15, females=6, Level of injury: C=3, T2-T7=7, T8-T12=7, L=4; Severity of injury: incomplete=13, complete=8; Control group: Mean age=38.1 yr; Gender: males=13, females=7, Level of injury: T2-T7=7, T8-T12=12, L=1; Severity of injury: incomplete=6, complete=14; <strong>Treatment:</strong> Those in the experimental group (n=21) were given an 8 wk home exercise program consisting of stretching and strengthening exercises. This program was augmented at 4 wk (or sooner). Changes included increasing elastic band resistance, increasing repetitions, or both. The asymptomatic control group (n=20) was not given any exercises. <strong>Outcome Measures:</strong> Wheelchair User's Shoulder Pain Index (WUSPI); Shoulder Rating Questionnaire (SRQ)</td>
<td>1. SRQ and WUSPI scores significantly improved in the experimental group, pre- to post-test (p&lt;0.001 and p=0.002, respectively). 2. Those in the asymptomatic control group did improve. 3. Over time, satisfaction scores in the intervention group significantly improved (p&lt;0.001).</td>
</tr>
<tr>
<td>Nash et al. 2007</td>
<td>Netherlands</td>
<td>Pre-Post</td>
<td>N=7</td>
<td></td>
<td><strong>Population:</strong> Age=39-58 yr; Level of injury=T5-T12; Severity of injury=complete. <strong>Treatment:</strong> Seven participants volunteered to undergo 16 weeks of circuit resistance training (CRT), 3 times weekly on non-consecutive days, each session lasting 45 min. Included were: circuit resistance training, low-intensity endurance activities, military press, horizontal rows, pectoralis (horizontal row), preacher curls, wide-grip latissimus pull-downs, and seated dips. <strong>Outcome Measures:</strong> Wheelchair User's Shoulder Pain Index (WUSPI)</td>
<td>1. Participants reported a reduction in pain. WUSPI scores decreased from 31.8±23.5 to 5.0±7.7 (p=0.008). 3/7 participants reported near-complete resolution of shoulder pain following treatment. 2. All completed training, with peak VO2 values increasing from 1.64±0.45 to 1.81±0.54L/min (p=0.01). 3. Anaerobic power increased significantly as a result of training; peak power increased by 6% and average power by 8.6% (p=0.005 and p=0.001, respectively).</td>
</tr>
</tbody>
</table>
**Author Year Country PEDro Score Research Design Total Sample Size**

**Methods**

**Finley & Rodgers 2007 USA Pre-Post N=17**

**Population:** Mean age=46 yr; Gender: males=9, females=8; Mean duration of wheelchair use=15 yr; Type of disability: SCI=9, spina bifida=1, ataxia=1, postpolio syndrome=1, spinal stenosis=1, stroke=1, rheumatoid arthritis=1.

**Treatment:** 4 wk baseline phase where patients used personal wheelchairs (no intervention), followed by a 5 mo phase where patients used the intervention wheelchair (MAGICWheels 2-gear wheel). There was a 4 wk retention period in which patients used their personal wheels again. Once a day patients were instructed to navigate in uneven terrain or on a hill.

**Outcome Measures:** Wheelchair User’s Shoulder Pain Index (WUSPI), WUFA, self-reported activities (Activities Log), and timed hill climb test with Rating of Perceived Exertion (RPE).

1. Shoulder ROM, upper-extremity strength, or the occurrence of specific shoulder diagnoses did not differ after use of MAGICWheels (p<0.05).
2. Shoulder pain was significantly decreased following the treatment at wk 2 (p=0.004) through wk 16 (p=0.015).
3. At wk 20, one patient reported increased pain from unrelated factor.
4. During the 4 wk retention phase, the WUSPI scores indicated a trend toward increasing shoulder pain. However, no significant increase was found compared to the last week of using the MAGICWheels (p<0.05).
5. During the MAGICWheels phase, patients encounter significantly more carpeted (p<0.01) and grass (p<0.001) surfaces in comparison to the baseline phase.
6. During the retention phase patients encountered significantly more hills (p=0.009) and gravel (p=0.03) surfaces in comparison to the baseline phase.
7. No difference was found in WUFA following the use of the 2-gear wheel (p=0.06).
8. There was significantly longer hill time during the use of the 2-gear wheel (p=0.01), however no difference was found in the RPE (p=0.013).

**Discussion**

Curtis et al. (1999) in a RCT studied the effectiveness of a 6-month exercise protocol on shoulder pain experienced by wheelchair users where 42 patients were randomized into a treatment and a control group. Over 75% of all subjects reported a history of shoulder pain since beginning wheelchair use and 50% in both groups had current shoulder pain at the start of the study. The treatment group performed two exercises designed to stretch the anterior shoulder musculature and 3 exercises for strengthening the posterior shoulder musculature. Compliance rates were higher-over 83% of the subjects completed the 6-month protocol. Subjects in the treatment group decreased their average PC- Wheelchair User’s Shoulder Pain Index (WUSPI) score by an average of 39.9% vs. only 2.5% in the control group. Despite this very significant change, 48.3% decreased in the paraplegic group and 27.2% in the tetraplegic group, the treatment group still had a higher mean score than the control group at the end of the study because of disparate baseline scores.
Nawoczenski et al. (2006) in a prospective controlled trial, found 21 SCI patients who participated in an ‘at-home’ exercise program experienced significant improvement in their WUSPI scores and on the Shoulder Rating Questionnaire (SRQ), when compared to subjects who did not participate in the exercise program. Exercises were designed to strengthen and stretch specific scapular and rotator cuff muscles. The authors concluded the exercises were effective at reducing pain and improving function.

In a pre-post study, Nash et al. (2007) reported that strength and anaerobic power of the upper extremities increased following 16 weeks of circuit training, while shoulder pain scores decreased significantly (p=0.008).

In a pre-post study (Serra-Ano et al. 2012) found that an 8 week resistance training program helped to reduce shoulder pain post SCI and improve shoulder functionality.

Finley and Rodgers (2007) studied 17 patients including 9 SCI patients with a special wheelchair (MAGIC wheels 2-gear wheelchair). They found use of this particular chair reduced shoulder pain.

Conclusion

There is level 2 evidence (from one prospective controlled trial and one pre-post study; Nawoczenski et al. 2006; Serra-Ano et al. 2012) that a shoulder exercise protocol reduces the intensity of nociceptive shoulder pain post-SCI.

There is level 4 evidence (from one pre-post study; Finley & Rodgers 2007) that the MAGIC wheels 2-gear wheelchair results in less nociceptive shoulder pain.

9.5 Behavioural Management of Pain Post SCI

9.5.1 Hypnotic Suggestions

Hypnosis has been used to reduce pain in a number of painful clinical conditions as well as experimental pain (Jensen et al. 2000). Hypnosis is appealing as a potential treatment because it is non-pharmacological although its use is controversial given the variability in hypnotic responsiveness.

Table 11 Hypnotic Suggestion Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jensen et al. 2009 USA</td>
<td>PEDro=5 RCT</td>
<td>RCT</td>
<td>Population: Mean Age=49.6yrs; Sex: males=28, females=9. Type of pain=Neuropathic</td>
<td>1. Individuals with neuropathic pain a significant decrease in daily pain intensity was seen in the hypnosis group post-session (p&lt;0.01) but not</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Author Year Country PEDro Score Research Design Total Sample Size

<table>
<thead>
<tr>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=37 randomized to receive either hypnosis or biofeedback. Individuals receiving hypnosis underwent 10 sessions of training daily or weekly. While the biofeedback group received 10 sessions of Electromyography biofeedback. <strong>Outcome Measures:</strong> Numeric Rating Scale (NRS)</td>
<td>2. Neither treatment was effective in reducing pain for individuals without neuropathic pain.</td>
</tr>
<tr>
<td><strong>Population:</strong> Age=24-76 yr; Gender: males=64%, females=36%; Time since injury=1.75-42.33 yr; Duration of pain=13.88 yr. Type of pain=Neuropathic and musculoskeletal <strong>Treatment:</strong> Hypnotic suggestions for pain relief were given to each subject. <strong>Outcome Measures:</strong> Pain intensity and unpleasantness and hypnotic responsiveness (modified version of the Stanford Hypnotic Clinical scale).</td>
<td>3. 86% reported decrease in pain intensity and unpleasantness from pre-induction to just after induction. 4. A significant time effect emerged for both pain intensity (p&lt;0.001) and pain unpleasantness (p&lt;0.001). 5. Significant effect for analgesic suggestion on pain intensity over and above the effects of the induction alone, with a significant decrease occurring in reported pain intensity before and after the analgesic suggestion (p&lt;0.05). 6. Pre-induction, post-induction, and post-analgesia suggestion pain intensity ratings were all significantly lower than average pain during the previous 6 months (p&lt;0.01, p&lt;0.0001, p&lt;0.0001 respectively). 7. Statistical significance was noted for two of the associations: Effect of pain plus analgesia suggestion on pain intensity (p&lt;0.01) and effect of induction alone relative to least pain (p&lt;0.05).</td>
</tr>
</tbody>
</table>

**Discussion**

Jensen et al. (2009) randomly allocated participants into hypnosis or the biofeedback treatment group. Participants in the hypnosis group reported a significant decrease in neuropathic pain intensity compared to those in the biofeedback group (p<0.01). However, no such effect was seen between the two groups in individuals without neuropathic pain. Jensen et al. (2000), in a before and after study, examined the impact of hypnosis on pain post-SCI. Eighty-six percent (86%) of the SCI patients reported a decrease in pain intensity and unpleasantness after hypnosis, although there was no control group.

**Conclusion**

*There is level 2 and level 4 evidence (from one randomized controlled trial and one pre-post study; Jensen et al. 2009, 2000) that hypnosis reduces neuropathic and musculoskeletal pain intensity post SCI.*

Hypnosis may reduce neuropathic and musculoskeletal pain intensity post SCI.
9.5.2 Biofeedback

Biofeedback involves training individuals to gain control over brain states through electroencephalography (EEG) in order to help improve pain intensity. Biofeedback has been previously been shown to improve pain intensity in individuals with fibromyalgia and migraines (Jensen et al. 2013).

Table 12 Biofeedback Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome Measures: Numeric Rating Scale (NRS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jensen et al. 2013 USA Pre-Post N=10</td>
<td>Population: Mean Age=46.1yrs; Sex: males=7, females=3; Time since Injury=12.3yrs Type of pain=Neuropathic and musculoskeletal</td>
<td>1. Significant improvement in worst pain intensity (p=0.01) and pain unpleasantness (p=0.026) was seen post treatment and at 3 month follow up.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jensen et al. 2009 USA PEDro=5 RCT N=37</td>
<td>Population: Mean Age=49.6yrs; Sex: males=28, females=9. Type of pain=Neuropathic</td>
<td>2. No significant improvement in average pain intensity or sleep was seen.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Discussion**

A pre-post study (Jensen et al. 2013) found biofeedback improved pain intensity among individuals with SCI pain. Jensen et al. (2009) randomly allocated participants into hypnosis or the biofeedback treatment group. Participants in the hypnosis group reported a significant decrease in neuropathic pain intensity compared to those in the biofeedback group (p<0.01). However, no such effect was seen between the two groups in individuals without neuropathic pain.

**Conclusion**

There is level 4 evidence (from one pre-post study; Jensen et al. 2013) that biofeedback may reduce neuropathic and musculoskeletal pain intensity post SCI.

Biofeedback may reduce neuropathic and musculoskeletal pain intensity post SCI.
9.5.3 Cognitive Behavioural Therapy

Cognitive behavioural therapy (CBT) is a commonly used psychological intervention for chronic pain. Often used as a part of a more comprehensive pain management program, it attempts to modify beliefs and coping skills, particularly when these beliefs and coping skills are dysfunctional.

Table 13 Cognitive Behavioural Therapy

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
</table>
| Heutink et al.    | 2012       | Netherlands  | PEDro=6     | RCT            | N=61              | Population: Mean age=58.8 yr; Gender: males=39, females=22; Duration of pain=5.4 yrs; Type of pain=neuropathic. Treatment: SCI Individuals with chronic neuropathic pain were randomly assigned to receive interdisciplinary pain management which included Cognitive behavioural therapy (CBT) and education or wait list control group. The intervention consisted of 10 sessions over 10 week period with a comeback session 3 weeks after the 10th session. | 1. Pain intensity decreased over time among the two group, p<0.01.  
2. Significant difference in pain intensity was seen between the two groups post intervention. However, no group difference between the two group were seen in pain intensity at 3 month follow-up.  
3. No significant difference in HADS depression was seen between the two groups or over time.  
4. Individuals in the CBT group found significant improvement in anxiety (p<0.027)and participation in activities (p<0.008) compared to the control group. |
| Burns et al.      | 2013       | Canada       | Pre-Post    | N=17           |                   | Population: Mean age=48 yr; Gender: males=11, females=6; Level of injury: tetraplegia=8, paraplegia=9, Severity of injury: complete=3, incomplete=14; Duration of pain>6 mo; Type of pain=neuropathic and musculoskeletal. Treatment: SCI Individuals with chronic pain were provided group based interdisciplinary pain management which included Cognitive behavioural therapy (CBT) self-management, and exercise biweekly for 10 weeks. | 1. No significant improvement in pain severity subscale of MPI was seen post intervention or at 12 months.  
2. Significant improvement in life interference and life control subscales was seen (p<0.01) up to the 12 month follow up. |
| Perry et al.      | 2010       | Australia    | Prospective Controlled Trial | N=36 |                   | Population: Mean age=43.8 yr; Gender: males=28, females=8; Level of injury: tetraplegia=13, paraplegia=20, Severity of injury: complete=13, incomplete=23; Duration of pain=60.5 mo; Type of pain=neuropathic and musculoskeletal. Treatment: SCI patients with chronic pain were placed in either the multidisciplinary cognitive behavioural pain management program (PMPs) group (N=19) which involved a pharmacological treatment plan and individual and group based cognitive behavioural therapy for pain; or the usual care group (N=17). | 5. At baseline, the PMP group had significantly worse usual pain intensity scores than the usual care group.  
6. A significant improvement was seen in MPI and SF-12 MCS scores in the PMP group compared to the control group post treatment (p=0.026, p=0.015).  
7. Mean scores of participants in the PMP group moved from moderate to mild disability.  
8. A trend towards improvement on the usual pain intensity and HADS depression score was seen in the PMP group at 1 mo post treatment; |
Author | Year | Country | PEDro Score | Research Design | Total Sample Size | Methods | Outcome
--- | --- | --- | --- | --- | --- | --- | ---
Norrbrink et al. 2006 | Sweden | Prospective Controlled Trial | N=38 | questionnaire; Multidimensional Pain Inventory (MPI); Hospital Anxiety and Depression Scale (HADS); SF-12 Mental Component Scale | however, the HADS depression scores returned to pre-treatment levels at 9 mo follow-up. | Population: SCI. Treatment: Mean age=53.2 yr; Gender: males=9, females=18; Control: Mean age=49.9 yr; Gender: males=5, females=6; Severity of injury: AIS A-E. Type of pain=Neuropathic |

**Population:** SCI. Treatment: Mean age=53.2 yr; Gender: males=9, females=18; Control: Mean age=49.9 yr; Gender: males=5, females=6; Severity of injury: AIS A-E. Type of pain=Neuropathic |

**Treatment:** SCI individuals were provided standard treatment of interdisciplinary pain management. The individuals in the interdisciplinary pain management participated in a 10 wk, 2x/wk treatment program which included four elements: 1) education (1.5 hr); 2) behaviour therapy (1.5 hr); 3) relaxation techniques and stretching/light exercise (1 hr); and 4) body awareness training (1hr). |

**Outcome Measures:** Pain Chart and pain rating was completed, pain intensity and unpleasantness was assessed with the Borg CR10 scale, Quality of sleep (survey), Nottingham Health Profile (Quality of life) was completed, Mood (Hospital Anxiety and Depression) was assessed, Coherence and use of the healthcare system were also assessed. |

1. From baseline to 12 mo evaluation period, the treatment group experienced decrease in:  
   - Anxiety and depression.  
   - Sleep.  
2. No change was seen over time in:  
   - Pain intensities and unpleasantness.  
   - Health-related quality of life.  
   - Life satisfaction.  
3. A significant improvement was noted for the Emotional Reaction subscale only (p<0.01).  
4. The two groups showed significant differences on the depression and SOC scores.  
5. A significant decrease in the number of visits between baseline and the 12 mo assessment period was noted for the treatment group (from 15 to 5; p<0.03), along with the median number of visits to physicians (from 3 to 1; p<0.03).  

Note: AIS=ASIA Impairment Scale

**Discussion**

Four studies examined the effectiveness of interdisciplinary pain management on chronic pain post SCI. Perry et al. (2010) placed SCI individuals with chronic pain into a multidisciplinary cognitive behavioural pain management program, involving pharmacological and CBT treatment, or in a usual care control group. This was the only study to find significant improvement in both the MPI and SF-12 MCS scores in the treatment group compared to the control group post treatment. A trend towards improved pain intensity and HADS score was also seen in the treatment group post treatment; however, scores returned to pre-treatment scores by 9 month follow-up. Norrbrink et al. (2006), Burns et al. (2013), and Heutink et al. (2012) found no improvement in pain intensity among individuals receiving treatment. However, both studies found significant improvement in related psychosocial factors post treatments. Norrbrink et al. (2006) found significant improvement in anxiety, depression and sleep interference post treatment. Burns et al. (2013) found change in life interference and locus of control. Significant improvement in anxiety and participation in activities was seen in Heutink et al. (2012) among individuals that received CBT.

**Conclusions**

*There is level 2 evidence (from one prospective controlled trial; Perry et al. 2010) that a cognitive behavioural pain management program with pharmacological treatment may improve secondary outcomes among SCI individuals with chronic pain post SCI.*
There is level 1b evidence (from one randomized controlled trial one prospective controlled trial, and one pre-post study; Heutink et al. 2012; Norrbrink et al. 2006; Burns et al. 2013) that cognitive-behavioural therapy alone does not change post-SCI pain intensity.


9.5.4 Visual Imagery

Visual imagery therapy is a cognitive technique which uses guided images to alter perceptions and modify behaviour. It has been used in various studies to alleviate pain responses by changing feelings of perceived discomfort (Kazdin 2001; Korn 2002; Kwekkeboom 2001). It is based on a cortical model of pathological pain (Harris, 1999). This model states that the injury causes a mismatch between motor output and sensory feedback which in turn contributes to the pain. Studies have found normalization of the cortical proprioception representation results in recovery from pain (Floor et al. 2000; Maihofner et al. 2004; Pleger et al. 2005).

Table 14 Visual Imagery

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soler et al.</td>
<td>2010</td>
<td>Spain</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>N=40</td>
<td>Population: Age=21-66 yr, Severity of injury: AIS A=32, B=8. Type of pain=Neuropathic Intervention: Patients were randomly divided into four groups: transcranial DCS and visual illusion group received direct current stimulation over C3 or 4 at a constant 2 mA intensity for 20 min and after 5 min of transcranial DCS video with someone walking was shown and the legs of person for 15 min with a vertical mirror so patients could see themselves walking; transcranial DCS group with control visual illusion received the above mentioned transcranial DCS however for the visual illusion only received a video of faces or landscapes, visual illusion group and sham transcranial DCS had electrodes placed on the same area as the treatment group however the stimulator was turned off after 30 s of stimulation and placebo group consisted of both the control visual illusion and the sham transcranial DCS. Outcome Measures: Numeric Rating Scale (NRS)</td>
<td>1. The most significant reduction in NRS of pain perception was seen in the combined transcranial DCS and visual illusion group compared to the visual illusion group (p=0.008) or the placebo group (p=0.004). 2. Pain reduction was also greatest in the transcranial DCS and visual illusion group than the other three groups at first and last follow up; however no difference was seen at second follow-up. 3. Visual illusion group was shown to have significant improvement in neuropathic pain intensity at last day of treatment (p=0.02); however, this effect was not maintained over the long term period. 4. Combined transcranial DCS and visual illusion group also showed significant improvement in ability to work, perform daily tasks, enjoyment, interference of pain in sleep (p&lt;0.05). 5. Transcranial DCS sessions were found to be safe, with minor side effects including mild headache.</td>
</tr>
<tr>
<td>Kumru et al.</td>
<td>2013</td>
<td>Spain</td>
<td>Cohort</td>
<td>N=52</td>
<td></td>
<td>Population: Age25-69yrs; Sex: male=34, female=18. Type of pain=Neuropathic and musculoskeletal, with a subanalysis of neuropathic</td>
<td>1. SCI individuals with neuropathic pain had a 37.4% improvement in pain intensity post treatment. 2. 13 of 18 individuals in the neuropathic</td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Gustin et al. 2008 Australia Pre-Post N=15</td>
<td>Treatment: Three cohorts of individuals (group 1(N=18)=SCI neuropathic pain; group 2(N=20)=SCI non-neuropathic pain; group 3(N=14)=healthy matched) underwent daily transcranial direct current stimulation along with visual illusion therapy for 2 weeks. The visual illusion involved the participant seated viewing a video of the matching gender walking on a treadmill. <strong>Outcome Measures:</strong> Numeric Rating Scale (NRS).</td>
<td>group reported 50% decrease in pain intensity post treatment. 3. Evoked pain perception was significantly lower in the neuropathic pain group compared to SCI nonneuropathic and healthy controls. 6. Pain threshold was significantly higher in the neuropathic pain group compared to the other two groups.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moseley 2007 UK Pre-Post N=5</td>
<td><strong>Population:</strong> SCI, Type of pain=Neuropathic <strong>Intervention:</strong> All participants were trained in movement imagery for seven days. Each participant was asked imagine right ankle plantarflexion and dorsiflexion for 8 min. <strong>Outcome Measures:</strong> McGill Pain Questionnaire (MPQ), Visual Analogue Scale (VAS).</td>
<td>1. Individuals with neuropathic pain reported a significant increase in pain intensity during movement imagery, p&lt;0.01. 2. Individuals without neuropathic pain reported a significant increase in non-pain intensity during movement imagery, p&lt;0.01.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Discussion

Soler et al. (2010) also examined the effectiveness of visual imagery for neuropathic pain post SCI. As indicated previously, the authors found the greatest improvement in pain perception, pain reduction, ability to work, perform daily tasks, enjoyment, interference of sleep in the combined tDCS and visual illusion group (p<0.05). Thirty percent of participants in this combined group also reported a 30% or more improvement in pain intensity. The visual illusion group reported significant improvement in neuropathic pain intensity on the last day of treatment (p=0.02); however, the effect was not maintained over 12 weeks.

Moseley (2007) reported on five individuals with both a T12-L3 paraplegia (AIS B) and neuropathic pain who engaged in a virtual activity, where they were led through a guided
walking exercise, visualizing that they were walking pain free. Of the four subjects who completed the trial (one patient withdrew from the study earlier due to distress), there was a mean 42 mm reduction in neuropathic pain following individual treatments, and 53 and 42 mm reductions immediately and 3 months following virtual walking daily for 3 weeks based on a 100 mm visual analog scale. Control treatments were visual imagery alone, and watching a movie, both of which resulted in less dramatic pain reduction; however, no statistical comparisons were done. One cohort study (Kumru et al. 2012) found that combined transcranial direct current stimulation and visual imagery may improve pain intensity among individuals with neuropathic pain post SCI.

Gustin et al. (2008) involved the participants to imagine right ankle plantarflexion and dorsiflexion for 8 minutes. In contrast to the studies above, a significant increase in neuropathic pain intensity post guided visual imagery, (p<0.01).

Conclusion

There is conflicting level 1b evidence (from one randomized controlled trial, a cohort study and two pre-post studies; Soler et al. 2010; Kumru et al. 2013; Gustin et al. 2008; Moseley 2007) that visual imagery may reduce at level neuropathic pain post SCI for a short period.

Visual imagery may reduce neuropathic pain post SCI

9.6 Transcranial Electrical Stimulation Post SCI Pain

Transcranial Electrical Stimulation (TCES) treatment involves applying electrodes to an individual's scalp to allow electrical current to be applied and presumably stimulate the underlying cerebrum (Tan et al. 2006).

Table 15 Transcranial Electrical Stimulation Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tan et al. 2006</td>
<td>USA</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>N=38</td>
<td>Population: Type of pain=neuropathic and musculoskeletal Treatment: Subjects received 1 hr Transcranial Electrical Stimulation (TCES) or sham TCES for 21 days to treat neuropathic or musculoskeletal pain. Following this, the control group was offered the opportunity to participate in an open-label TCES study. Outcome Measures: Brief Pain Inventory (BPI)</td>
<td>1. No significant difference between TCES and sham groups for BPI. However, several individual interference items were significantly reduced, from pre to post intervention, in the TCES group only. 2. For active TCES, average daily pain intensity from pre to post assessment decreased significantly (p=0.03) compared to the sham (control) group. 3. Significant reduction in daily pain intensity noted in treatment group (pre-post) (p=0.02) but not in control group (p=0.34). 4. During open label trial, a reduction in pain was noted after TCES treatment (p=0.003)</td>
</tr>
<tr>
<td>Fregni et al. 2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Population: Type of pain=neuropathic.</td>
<td>1. Treatment produced significant</td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>USA</td>
<td>PEDro=9</td>
<td>RCT</td>
<td>N=17</td>
<td>Treatment: Subjects received either sham (10 sec of stimulation with same procedure but then turned off) or active tDCS (2 mA, 20 min for 5 days).</td>
<td>Outcome Measures: VAS</td>
<td>decrease in pain scores over time (p&lt;0.0001). 2. The largest pain reduction was noted after session five; effect decreased during follow-up, though pain scores remained lower than baseline scores. 3. There was no significant effect of treatment on either anxiety or depression scores in either group. 4. Effects on cognitive function similar for tDCS and sham.</td>
</tr>
<tr>
<td>Capel et al. 2003</td>
<td>USA</td>
<td>PEDro=9</td>
<td>RCT</td>
<td>N=30</td>
<td>Population: Type of pain=neuropathic and musculoskeletal Treatment: SCI subjects randomly assigned to one of two groups. Treatment group received transcranial electrostimulation (TCES) twice daily for 4 days, while controls received sham treatment. After an 8 wk washout period, treatments were reversed for sham treatment group only; thus, during the second half of the observation period, all received active treatment. Three subjects left the study early, two because of interactions between TCES and medications.</td>
<td>Outcome Measures: Short form McGill Pain Questionnaire (SF-MPQ); State Trait Anxiety Inventory (STAI); Beck Depression Inventory (BDI)</td>
</tr>
<tr>
<td>Soler et al. 2010</td>
<td>Spain</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>N=40</td>
<td>Population: Age=21-66yr, Severity of injury: AIS A=32, B=8. Intervention: Patients were randomly divided into four groups: transcranial DCS and visual illusion group received direct current stimulation over C3 or C4 at a constant 2 mA intensity for 20 min and after 5 min of transcranial DCS video with someone walking was shown and the legs of person for 15 min with a vertical mirror so patients could see themselves walking; transcranial DCS group with control visual illusion received the above mentioned transcranial DCS; however, for the visual illusion only received a video of faces or landscapes, visual illusion group and sham transcranial DCS had electrodes placed on the same area as the treatment group however the stimulator was turned off after 30 sec of stimulation and placebo group consisted of both the control visual illusion and the sham transcranial DCS.</td>
<td>Outcome Measures: Numeric Rating Scale (NRS)</td>
</tr>
<tr>
<td>Yoon et al. 2014</td>
<td>Korea</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>N=40</td>
<td>Population: Mean =44.1yr; Gender:</td>
<td>1. Individuals in the active group had</td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------</td>
<td>----------------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea</td>
<td></td>
<td>4.0</td>
<td>Prospective Controlled Trial</td>
<td>N=16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Methods**
- Male=12, female=4. Type of pain: neuropathic; Time since injury>6months.
- **Treatment**: SCI individuals with chronic neuropathic pain received either active or sham transcranial direct current stimulation for 20 minutes, 2 times a day for 10 days.
- **Outcome Measures**: Numeric Rating Scale (NRS); Patient Global Impression of Change (PGIC)

**Outcome**
- Significant reduction in pain intensity post treatment (p=0.016).
- 2 individuals in the treatment group experienced reduction in pain intensity of greater than 30%, with the group average of 22.9% reduction.
- No significant difference was seen between the two groups in PGIC.

| Kumru et al. 2013 | Spain | 4.0 | Cohort | N=52 |

**Population**: Age=25-69yrs; Gender: male=34, female=18. Type of pain=Neuropathic and musculoskeletal, with a subanalysis of neuropathic.
- **Treatment**: Three cohorts of individuals (group 1(N=18)=SCI neuropathic pain; group 2(N=20)=SCI non-neuropathic pain; group 3(N=14)=healthy matched) underwent daily transcranial direct current stimulation along with visual illusion therapy for 2 weeks. The visual illusion involved the participant seated viewing a video of the matching gender walking on a treadmill.
- **Outcome Measures**: Numeric Rating Scale (NRS)

**Outcome**
- SCI individuals with neuropathic pain had a 37.4% improvement in pain intensity post treatment.
- 13 of 18 individuals in the neuropathic group reported 50% decrease in pain intensity post treatment.
- Evoked pain perception was significantly lower in the neuropathic pain group compared to SCI nonneuropathic and healthy controls.
- Pain threshold was significantly higher in the neuropathic pain group compared to the other two groups.

**Discussion**

Despite the fact that TCES is a relatively new treatment for post-SCI pain, 4 RCTs (Capel et al. 2003; Fregni et al. 2006; Soler et al. 2010; Tan et al. 2006) have been published; all of the studies suggest that it may be useful in reducing SCI-related chronic pain. Each of these investigations employed a sham stimulation control condition, using modified equipment. Although patients in all 3 studies reported some pain relief following treatment, there was no comment on how long the treatments should continue or how often they should be used.

Soler et al. (2010) divided participants into four groups: the tDCS group, visual illusion group, combined tDCS and visual illusion group and the control group. The tDCS group received direct current simulation over C3 or C4 at a constant 2mA intensity for 20 minutes along with a control visual illusion which involved watching a video of faces or landscapes. The actual visual illusion group was provided with a sham tDCS treatment, after 5 minutes they were shown a video of someone walking in front of a vertical mirror so patients perceive themselves walking for 15 minutes. The combined tDCS and visual illusion group received active treatment for both, while the last group, the control group, received inactive treatment for both tDCS and visual illusion group. Each participant received a total of 10 sessions of therapy, 20 minutes each for 2 weeks. The study found significant improvement in NRS pain perception, pain reduction, ability to work, perform daily tasks, enjoyment, and interference of pain in sleep (p<0.05) in the combined tDCS and visual illusion group compared to the other groups. The study showed clinical significance where 30% improvement in pain intensity was seen in 30% of participants in the combined group.
Tan et al. (2006) conducted a double-blind RCT with 38 SCI participants with either chronic musculoskeletal or neuropathic pain receiving either active TCES or inactive TCES (sham control) over 21 days. The electrical stimulation was set at a subthreshold level ensuring that patients were blind to their treatment group. The study found that SCI patients receiving transcranial electrotherapy stimulation (n=18) experienced a significant reduction in post-SCI neuropathic and musculoskeletal average daily rating of pain intensity (p=0.03); however, there was no significant reduction in pain as noted on the Brief Pain Inventory (BPI).

Capel et al. (2003) reported that TCES resulted in lower pain scores on the McGill Pain Questionnaire for those in the treatment group (n=15), while those in the control group (n=15) reported no change. No statistical differences were noted across different pain types, although the authors did comment that subjects had greater relief of visceral pain following each active 4-day treatment phase of the study. TCES was associated with a reduction in the use of analgesics and antidepressants.

Fregni et al. (2006) found similar results after examining the effects of transcranial direct current stimulation (tDCS) on central neuropathic pain. The treatment group (n=11), those receiving active tDCS for 5 consecutive days, experienced a significant reduction in pain relief over time (p<0.0001) compared to those receiving sham treatments (n=6).

One prospective controlled study (Yoon et al. 2014) found that 10 days of active transcranial direct current stimulation significantly improved pain intensity compared to sham treatment. One cohort study (Kumru et al. 2012) found that combined transcranial direct current stimulation and visual imagery may improve pain intensity among individuals with neuropathic pain post SCI.

Conclusion

There is strong evidence level 1a evidence (from four randomized controlled trials; Capel et al. 2003; Fregni et al. 2006; Soler et al. 2010; Tan et al. 2006) for the benefits of transcranial electrical stimulation in reducing neuropathic and neuropathic and musculoskeletal post-SCI pain.

Transcranial electrical stimulation is effective in reducing post SCI neuropathic pain.

9.7 Static Magnetic Field Therapy Post SCI Pain

Table 16 Static Magnetic Field Therapy Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panagos et al. 2004</td>
<td>USA</td>
<td>Pre-Post</td>
<td>N=8</td>
<td>Population: Type of pain=nociceptive musculoskeletal shoulder pain. Treatment: A concentric field type magnet (500 gauss) was placed over one shoulder for 1 hr. Outcome Measures: Short form McGill Pain Questionnaire (SF-MPQ); Visual Analogue Scale (VAS)</td>
<td>1. On SF-MPQ, pain intensity decreased (p&lt;0.01). 2. Significant decreases also were noted in severity of sharp and stabbing pain, and degree of tenderness (p=0.033, p=0.02, and p=0.021, respectively). 3. Pain intensity on VAS and in response to pressure did not change significantly with magnet application.</td>
<td></td>
</tr>
</tbody>
</table>
Discussion
Static Magnetic Field (SMF) therapy has been studied as a treatment for pain post SCI. Panagos et al. (2004) in a pre-post study involving eight individuals, on average 12 years post injury, found that placing a static field magnet of 500 gauss over a self-identified ‘trigger point’ resulted in patients reporting less stabbing, sharp and tender pain (p<0.05); however, there was no significant change noted on a VAS pain severity scale. These results are severely limited by the uncontrolled study design and relatively few study participants.

Conclusion
There is level 4 evidence (from one pre-post study; Panagos et al. 2004) that using a static field magnet helps to reduce reports of sharp, stabbing nociceptive shoulder pain but does not significantly reduce the VAS score of pain in individuals with a SCI.

9.8 Transcutaneous Electrical Nerve Stimulation for Pain Post SCI
Transcutaneous Electrical Nerve Stimulation (TENS) is commonly used as an electroanalgesic and has been shown to be efficacious in the treatment of chronic musculoskeletal pain (Johnson et al. 2007). TENS is believed to preferentially stimulate large alpha sensory nerves and reduce pain at the presynaptic level in the dorsal horn of the spinal cord through nociceptive inhibition (Cheing et al. 1999).

Table 17 Transcutaneous Electrical Nerve Stimulation for Pain Post SCI

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yeh et al. 2010</td>
<td>Taiwan</td>
<td>PEDro=6</td>
<td>RCT</td>
<td>N=99</td>
<td>Population: Mean age: 60.4 yr. Treatment: Patients who previously underwent surgery for non-traumatic SCI were randomized to one of three groups: 1) true acupoint intervention through electrical stimulation; 2) sham acupoint; 3) no treatment.</td>
<td>1. Significant difference was seen in pain intensity between the true acupoint group and sham group (p&lt;0.03) and the true acupoint group and control group (p&lt;0.02). 1. A significant reduction was also seen in the impact of pain on sleep in the true acupoint group compared to the other two groups (p&lt;0.05).</td>
</tr>
<tr>
<td>Norrbrink 2009</td>
<td>Sweden</td>
<td>Prospective Controlled Trial</td>
<td>N=24</td>
<td>Population: Age=47.2yr; Gender: males=20, females=4; Level of injury: C=13, T=8, L=3. Type of pain=Neuropathic and musculoskeletal intervention: Patients were provided with either low frequency (2Hz) or high frequency (80Hz) transcutaneous electrical nerve stimulation (TENS) stimulation for 30-40 min 3x/day for 2 wk followed by a 2 wk washout period and switched stimulation frequency.</td>
<td>1. No significant difference was found between the two modes of stimulation. 2. 21% reported reduction of greater than or equal to 2 units of general pain intensity (more than 1.8 considered significant clinical reduction), 29% in worst pain intensity and 33% in pain unpleasantness. 2. 29% reported a favorable effect on the global pain relief scale from HF and 38% from LF stimulation.</td>
<td></td>
</tr>
<tr>
<td>Davis &amp; Lentini 1975</td>
<td>USA</td>
<td></td>
<td></td>
<td>Population: Type of pain=Neuropathic Treatment: Patients were tested with</td>
<td>3. Those with a cervical injury (n=4) were not successfully treated with</td>
<td></td>
</tr>
</tbody>
</table>
**Table 18 Transcranial Magnetic Stimulation**

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jette et al. 2013</td>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
<td>Population: SCI: Mean age=50yr; Gender: males=11, females=5; Level of</td>
<td>1. Significant reduction in pain was seen in both hand (p=0.003) and leg</td>
</tr>
</tbody>
</table>

**Discussion**

Norrbrink (2009) in a crossover study examined the effect of low frequency (2Hz) or high frequency (80Hz) TENS stimulation. Patients received either low or high frequency stimulation for 30 to 40 minutes 3 times a day for 2 weeks followed by a 2 week washout period. They then switched stimulation frequency groups. The authors reported no significant difference between the two treatments in improving neuropathic pain. However, the study did find clinically significant reductions of pain intensity, worst pain intensity and pain unpleasantness post treatment when compared to baseline scores. In 70% of participants there was a decrease of greater than 2 points in pain intensity from baseline; where clinical significance was defined as having a reduction of greater than 1.8 points.

Davis and Lentini (1975) reported on a series of patients (n=31) in whom transcutaneous nerve stimulation was applied to painful areas. Among those with a thoracic (n=11) or caudal level injury (n=16), only 36% reported that the treatment was successful in reducing pain at the injury site; meanwhile, none of those with a cervical injury (n=4) experienced any reduction in pain. In general, TENS was not deemed effective for radicular or below-level injury site pain.

**Conclusion**

*There is level 4 evidence (from one case series study; Davis & Lentini 1975) that transcutaneous electrical nerve stimulation reduced at-the-injury site pain in only a minority of patients with thoracic or cauda equina SCI, but not those with cervical SCI.*

Transcutaneous electrical nerve stimulation may reduce pain at site of injury in patients with thoracic but not cervical injury.

**9.9 Transcranial Magnetic Stimulation**

Transcranial magnetic stimulation (TMS) is a non-invasive and relatively safe technology where electromagnetic currents in a coil produces magnetic pulses which crosses the cranium and induces neuron depolarization (Defrin et al. 2007). Magnetic stimulation of the motor cortex has been shown to attenuate post-stroke pain (Migita et al. 1995).
## Discussion

Jette et al. (2013) found individuals receiving active rTMS had significant reduction in pain intensity up to 48 hours post treatment. Defrin et al. (2007) found that both real and sham TMS stimulated treatments significantly reduced pain although the real TMS treatment resulted in a much greater reduction in pain and depression scores at follow-up.
Conclusion

There is level 1a evidence (from two randomized controlled trials; Jette et al. 2013; Defrin et al. 2007) that transcranial magnetic stimulation significantly reduced post-SCI neuropathic pain significantly over the long-term.

Transcranial magnetic stimulation reduces post-SCI neuropathic pain.

10.0 Pharmacological Management of Post-SCI Pain

Pharmacological interventions are the standard treatment for SCI pain. The limited effectiveness of non-pharmacological treatments has contributed to increasing use of pharmacological interventions to deal with what is often very severe and disabling pain.

10.1 Pharmacological Measures Overall

Table 19 Pharmacological Interventions and Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year; Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Widerström-Noga &amp; Turk 2003</td>
<td>USA</td>
<td>Case control N=120</td>
<td>Population: Mean age=40.6 yr; Gender: males=94, females=26; Level of injury=cervical, non-cervical; Time since injury=9.8 yr. Treatment: Individuals with SCI related pain filled out a questionnaire; data from the questionnaire was analysed by dividing individuals into two groups: those that received pain treatment and those that did not. Outcome Measures: Sociodemographic data and characteristics of injury, intensity of pain, location of pain, quality of pain, allodynia (pain in response to a stimulus that would not provoke pain), Multidimensional Pain Inventory (MPI) (designed to assess the impact of pain and adaptation to chronic pain), difficulty in dealing with pain and pain treatments.</td>
<td>Overall 59.2% of participants used pharmacological or non-pharmacological treatments to control pain. 40.8% indicated they had not used nor had they been prescribed any medication for pain. 1. Pain Severity: Pain severity was found to be higher for those who had received pain medications (PM) (3.9±1.3, p=0.001) compared to those who had not used any pain treatment. The intensity of pain was higher for those on PM than for those not on PM (p=0.022). 2. Pain Locations: Those using PM reported more painful areas than those not using PM (p=0.001) with frontal/genital pain reported more often (p&lt;0.000). 3. Quality of Pain: Those on PM used more descriptive adjectives to describe their pain compared to those not using PM (p=0.031). 4. Difficulty in Dealing with Pain: Those using PM reported having more difficulty dealing with pain than those not using PM (p&lt;0.000). 5. Pain impact: Those using PM had higher scores for the pain severity scale and the life interference scale compared to the group not using PM (p&lt;0.002).</td>
<td></td>
</tr>
</tbody>
</table>

Discussion
Widerström-Noga and Turk (2003), not unexpectedly, found that SCI patients with more severe pain, in more locations, those with allodynia or hyperalgesia, and those in whom the pain was more likely to interfere with activities were more likely to use pain medications.

Trials of simple non-narcotic analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen or non-narcotic “muscle relaxants” are common clinical practice in SCI pain. Unfortunately, these medications are often ineffective in complete SCI neuropathic pain relief and have potential risks such as gastric ulceration with prolonged use.

For neuropathic or “central” pain seen following SCI, psychotropic drugs such as antidepressants and anticonvulsants are reportedly the most effective (Donovan et al. 1982). Despite increasing popularity, few drugs (with the exception of Gabapentin and pregabalin) have regulatory approval for use in neuropathic pain and selection for individual patients is largely based on anecdotal evidence, of off-labelled use.

10.2 Anticonvulsants in SCI Pain

Anticonvulsant medications are often utilized in treating neurogenic or deafferent pain following SCI based on the theory that these drugs alter sodium conduction in uncontrolled hyperactive neurons (“convulsive environment”) in the spinal cord. Carbamazepine has been reported as being somewhat effective in the paroxysmal, sharp, shooting pain of trigeminal neuralgia (Swerdlow 1984). Gibson and White (1971) described relief resulting from carbamazepine treatment in two cases of L2 and T8 SCI with intractable pain below the level of SCI. A similar effect of Carbamazepine (200 mg 2x daily in combination with Amitriptyline 50 mg 3x daily) was reported in a complete C8 patient with dysesthesia below the level of the injury (Sandford et al. 1992). Again, controlled studies utilizing these drugs in SCI pain are lacking with the exception of gabapentin and pregabalin.

Gabapentin and pregabalin are now regarded as first-line treatments of neuropathic pain (Ahn et al. 2003; Moulin et al. 2007). Gabapentin and pregabalin have been recommended as first line treatments for neuropathic pain in Canadian and international guidelines (Gajraj 2007). The mechanism of action for Pregabalin and Gabapentin is through binding the alpha-2 delta receptors in the central nervous system. These receptors are present on the presynaptic nerve terminals. When bound by gabapentin or pregabalin they decrease the influx of calcium into the presynaptic terminal thereby decreasing the release of excitatory neurotransmitters. Gabapentin and pregabalin appear to potentiate GABA effects centrally through enhancement of GABA synthesis and release. Levendoglu et al. (2004) noted that neuropathic pain is ultimately generated by excessive firing of pain-mediating nerve cells, insufficiently controlled by segmental and non-sequential inhibitory circuits. Gabapentin and pregabalin work by increasing GABA and reducing the release of glutamate thereby suppressing the sensitivity of N-methyl-D-aspartate (NMDA) receptor. This has been shown to reduce neuronal hyper-excitability recorded at the spinal dorsal horn near the level of injury (Ahn et al. 2003). Gabapentin and pregabalin are relatively well tolerated with only a few transient side effects, lack of organ toxicity, and no evidence of significant interaction with other medications (Levendoghu et al. 2004; Gajraj 2007).

Table 20 Anticonvulsants for SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabapentin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------</td>
<td>----------------</td>
<td>------------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Rintala et al. 2007; USA</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>N=38</td>
<td>Population: SCI. Mean age=42.6 yr; Gender: males=20, females=2; Level of injury: paraplegia=7, tetraplegia=12; Severity of injury: AIS A-C=19, D=3; Time since injury=12.6 yr; Duration of pain=7.3 yr. Type of pain=Neuropathic Treatment: Patients were randomized into one of six groups: 1) gabapentin-amitriptyline-diphenhydramine (GAD; n=7); 2) GDA (n=6); 3) AGD (n=6); 4) ADG (n=6); 5) DGA (n=7); 6) DAG (n=6). Each drug was administered for 9 wk with one washout week before and after each drug treatment, for a total of 31 wk. The maximum doses were 50mg 3x/day for amitriptyline, 1200mg 3x/day for gabapentin, and 25mg 3x/day for diphenhydramine (control).</td>
<td>1. Amitriptyline was significantly more effective than diphenhydramine at 8 weeks, in subjects with high (≥10) baseline CESD-SF scores (p=0.035). 2. No significant difference was seen at 8 weeks in subjects with high (≥10) baseline CESD-SF scores in: a) Effectiveness of amitriptyline over gabapentin (p=0.061). b) Effectiveness of gabapentin over diphenhydramine (p=0.97). 3. Subjects with low (&lt;10) baseline CESD-SF scores showed no significant difference among the medications.</td>
<td></td>
</tr>
<tr>
<td>Levendoglu et al. 2004; Turkey</td>
<td>PEDro=9</td>
<td>RCT</td>
<td>N=20</td>
<td>Population: Age=23-62 yr; Gender: males=13, females=7; Onset of pain post injury=1-8 mo; Duration of pain=6-45 mo. Type of pain=Neuropathic Treatment: Subjects were randomized to gabapentin or placebo for a 4 wk titration period. Following this 4 wk period subjects continued to receive max tolerated doses. After a 2 wk washout period the treatments were switched in a crossover design.</td>
<td>1. Both placebo and the gabapentin improved pain scores for the following: pain intensity (p&lt;0.000), shape (p&lt;0.000), hot (p&lt;0.001), unpleasantness (p&lt;0.000), deep and surface pain (p&lt;0.001), at week 4 and 8 of administration. 2. Intensity of pain decreased significantly for the gabapentin groups during treatment p&lt;0.001) and the intensity of pain differed between the two groups at all time periods (p&lt;0.001). 3. VAS scores indicated that there was significant pain relief, which began at week 2 and continued until week 6 (p&lt;0.05) and pain relief between the two groups at the end of the stable dosing periods was significantly different (p&lt;0.000). 4. More experienced side effects in the treatment group then in the placebo group (p&lt;0.05).</td>
<td></td>
</tr>
<tr>
<td>Tai et al. 2002 USA</td>
<td>PEDro=6</td>
<td>RCT</td>
<td>N=7</td>
<td>Population: Age=27-47 yr; Gender: males=6, females=1; Level of injury=C2-T7; Time since injury=1 mo-20 yr. Type of pain=Neuropathic Treatment: Subjects with neuropathic pain were treated with gabapentin or placebo.</td>
<td>1. Significant reduction of &quot;unpleasant feeling&quot; with gabapentin vs. placebo (p=0.028). 2. Trends of reductions with gabapentin vs. placebo for &quot;pain intensity&quot; (p=0.094) and &quot;burning feeling&quot; (p=0.065). 3. No other differences for any other pain descriptors including &quot;sharp,&quot; &quot;dull,&quot; &quot;cold,&quot; &quot;sensitive,&quot; &quot;itchy,&quot; &quot;deep,&quot; and &quot;surface.&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Population: Age=15-75 yr; Gender: males=28, females=10; Level of injury:</td>
<td></td>
<td>1. 76% of subjects reported some improvement in pain after taking</td>
</tr>
<tr>
<td>Author Year Country PEDro Score Research Design Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>To et al. 2002 Australia Case Series N=44</td>
<td>paraplegia, tetraplegia. Type of pain=Neuropathic Treatment: Neuropathic pain was treated with gabapentin. Outcome Measures: Level of pain experienced by subjects.</td>
<td>gabapentin. 2. Visual Analogue Scores decreased from 8.86 pre-treatment to 4.13 post-treatment (6 mo later) (p&lt;0.001), with a significant curvilinear trend (p=0.001).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahn et al. 2003 Korea Pre-post N=31</td>
<td>Population: Mean age=45 yr; Gender: males=19, females=12; Level of injury: paraplegia, tetraplegia; Severity of injury: complete, incomplete; Duration of pain=10 yr. Type of pain=Neuropathic Treatment: Subjects were started on 300 mg of gabapentin, which was increased over 18 days to 1500 mg, followed by a 5 wk maintenance period. If pain score did not decrease during this time period, meds were increased to 2400 mg/day and 3600 mg/day. Group 1 had &lt;6 mo of pain and group 2 &gt;6 mo. Outcome Measures: Pain and sleep interference scores of the two groups were compared.</td>
<td>1. At the end of the study, both groups showed they had lower mean scores for pain and sleep interference score (p&lt;0.05). 2. Mean pain score for Group 1 decreased more than it did for Group 2 (p&lt;0.05). 3. This score decreased more for Group 1 during wk 2-8 than it did for Group 2 (p&lt;0.05). 4. Mean sleep interference score for Group 1 decreased more than it did for Group 2 (p&lt;0.05).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Putzke et al. 2002 USA Observational N=21</td>
<td>Population: Gender: males=76%, females=24%; Level of injury: paraplegia=67%, tetraplegia=33%; Severity of injury: incomplete=76%, complete=33%; Type of pain=Neuropathic Treatment: Participants were asked to complete a survey (or interview). Outcome Measures: Numeric Rating Scale (NRS)</td>
<td>1. 67% of patients reported having had a favourable response to gabapentin. 2. Among those reporting a favourable response, side effects were forgetfulness and sedation. 3. Among those interviewed a second time, most who reported a favourable response were using other medications and gabapentin for pain. 4. Side effects like sedation and forgetfulness were common.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas et al. 2013 USA PEDro=10 RCT N=219</td>
<td>Population: Mean age=45.7yrs; Gender: Male=176; Female=43 Treatment: SCI individuals with neuropathic below level pain for greater than 3 months were randomized to a twice daily pregabalin group (up to 600mg/d) or placebo for 12 weeks. Outcome Measures: Duration-adjusted average change in pain.</td>
<td>1. Significant improvement in pain was seen in the treatment group compared to placebo, p=0.0003. 2. Significant improvement in pain related sleep interference scores were seen post treatment in the pregabalin group compared to placebo, p&lt;0.05.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sidall et al. 2006 Australia PEDro=9 RCT N=137</td>
<td>Population: Mean age=45 yr; Gender: males=19, females=12; Level of injury: paraplegia, tetraplegia; Severity of injury: complete, incomplete; Duration of pain=10 yr. Type of pain=Neuropathic Treatment: Patients were randomized to either flexible-dose pregabalin 150 to 600 mg/day (n=70) or placebo (n=67), administered BID Outcome Measures: Pain scores, sleep interference and anxiety scores of the two groups were compared.</td>
<td>1. The mean baseline pain score was 6.54 in the pregabalin group and 6.73 in the placebo group. 2. The mean endpoint pain score was lower in the pregabalin group (4.62) than the placebo group (6.27; p&lt;0.001). 3. Efficacy observed as early as wk 1 and maintained for the duration of the study. 4. The average pregabalin dose after the 3 wk stabilization phase was 460 mg/day.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Year Country</td>
<td>PEDro Score Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vranken et al. 2008 Netherlands PEDro=9 RCT N=40</td>
<td><strong>Population:</strong> Treatment group: Mean age=54.2 yr; Gender: males=11, females=9; Control group: Mean age=54.7 yr; males=10, females=10. Type of pain=Neuropathic <strong>Treatment:</strong> Those in treatment group received escalating doses of pregabalin (150 mg, 300 mg, or 600 mg daily), while the control group received placebo. <strong>Outcome Measures:</strong> Visual Analogue Scale (VAS)</td>
<td></td>
<td>5. Pregabalin was associated with improvements in disturbed sleep (p&lt;0.001) and anxiety (p&lt;0.05) 6. Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arienti et al. 2011 Italy RCT PEDro=6 N=47</td>
<td><strong>Population:</strong> Severity of injury: AIS A=33; B, C and D=14. Level of injury: paraplegia=19, tetraplegia=7. Type of pain=Neuropathic <strong>Intervention:</strong> Patients were randomly placed into three groups: pharmacological group received 600 mg per day of pregabalin. The pharmacological and osteopathic group received 600mg per day of pregabalin and osteopathic treatment once a week for the first month, once every fortnight for the second month, once during the third month all for 45 min each by an osteopathic physician. The osteopathic group received on the osteopathic treatment described above. <strong>Outcome Measures:</strong> Verbal numeric scale (VNS)</td>
<td></td>
<td>1. 82.5% of subjects completed the study. 2. Those in the treatment group experienced a decrease in pain (p&lt;0.01) compared to control group. 3. With respect to health status and quality of life, treatment group experienced a statistically-significant improvement, in particular on the EQ-5D VAS and EQ-5D utility scores (p&lt;0.01). 4. Scores on the SF-36 showed significant improvement in the bodily pain domain (p&lt;0.009) for the treatment group, but not in other domains. 5. The highest pain relief was seen in the combined pharmacological and osteopathic group compared to the pharmacological alone (p=0.05) and the osteopathic alone (p=0.001).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finnerup et al. 2002 Denmark PEDro=10 RCT N=30</td>
<td><strong>Population:</strong> SCI patients with pain at or below the level of injury. Type of pain=Neuropathic <strong>Treatment:</strong> A 1 wk baseline period was followed by two treatment periods of 9 wk. Lamotrigine slowly increased to a maximum of 400 mg or placebo separated by a 2 wk washout period. <strong>Outcome Measures:</strong> The primary outcome measure was the change in median pain score from baseline week to the last week of treatment. Secondary outcome measures included thresholds to standardized sensory stimuli using quantitative sensory testing.</td>
<td></td>
<td>1. Twenty-two patients completed the trial. 2. No statistically significant effect of lamotrigine as evaluated in the total sample 3. In patients with incomplete SCI, lamotrigine significantly reduced pain at or below SCI level. 4. Patients with brush evoked allodynia and wind-up-like pain in the area of maximal pain were more likely to have a positive effect to lamotrigine than patients without these evoked pains.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Levetiracetam**
<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finnerup et al. 2009</td>
<td>Denmark</td>
<td>PEDro=7</td>
<td>RCT</td>
<td>N=36</td>
<td><strong>Population:</strong> Mean age=52.8 yr; Gender: males=29, females=7; Level of injury: C=13, T=19, L=4; Severity of injury: AIS A=13, B=2, C=3, D=18; Type of pain: at level=17, below level=31.</td>
<td><strong>Treatment:</strong> Patients were randomized into two 5 week treatment groups receiving either levetiracetam or placebo tablets. After a 1 wk washout period, individuals were crossed over to the 2nd group. Patients received 500 mg x2 for the first week, 1000mg x2 in the second week, and 1500 mg x2 in wk 3-5. Patients were assessed at baseline, end of each treatment and 6 mo follow-up. <strong>Outcome Measures:</strong> Neuropathic pain symptom inventory</td>
</tr>
<tr>
<td>Drewes et al.1994</td>
<td>Denmark</td>
<td>PEDro=5</td>
<td>RCT</td>
<td>N=20</td>
<td><strong>Population:</strong> Mean age=32.5 yr; Gender: males=15, females=5; Level of injury: paraplegia=16, tetraplegia=4; Type of pain=neuropathic.</td>
<td><strong>Treatment:</strong> Subjects were administered 600 mg of valproate or placebo 2x daily. Daily dose of valproate was increased (on an individual basis) if pain persisted and no side effects were reported. First treatment phase lasted 3 wk, followed by a 2 wk washout period, followed by 3 wk of cross-over treatment. <strong>Outcome Measures:</strong> McGill Pain Questionnaire (MPQ)</td>
</tr>
</tbody>
</table>

**Note:** AIS=ASIA Impairment Scale

**Discussion**

**Gabapentin**

To et al. (2002) studied the impact of gabapentin on pain in a case series of 44 SCI patients with neuropathic pain and reported a significant decrease (p<0.001) in visual analogue pain scale (VAS) in 76% of subjects. Tai et al. (2002) studied the impact of gabapentin for pain treatment in a small RCT of only 7 patients. There was a significant reduction of “unpleasant feeling” with gabapentin vs. placebo (p=0.028) while “pain intensity” and “burning pain” only trended to significance (p=0.094 and 0.065, respectively) and no differences were detected for other pain descriptors such as “sharp”, “dull”, “cold”, “sensitive”, “itchy”, “deep”, “surface”. Levendoglu et al. (2004) in a cross-over design of 20 paraplegics with neuropathic pain > 6 months found that Gabapentin was more effective (p<0.05) than placebo in reducing neuropathic pain. Ahn et al. (2003) in a before and after trial found that Gabapentin was effective (p<0.05) in decreasing neuropathic pain which was refractory to conventional analgesics for SCI patients with pain<6 months and > 6 months and that the impact was greater for those patients with pain<6 months in the most recent pain group. Putzke et al. (2002) found that, among the 21 patients who answered their questionnaire, 67% (n=14) reported a reduction in pain while on gabapentin.
Rintala et al. (2007) was the only study to report Gabapentin to have no benefit over placebo in the treatment of pain in spinal cord injury. This study may have been complicated by the fact that the placebo treatment was dimenhydrinate and not a true inert placebo and the number of subjects was only twenty-two.

**Pregabalin**

Pregabalin is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA) with demonstrated analgesic, anxiolytic, and anticonvulsant activity. It's mechanism of action is similar to gabapentin, but it has a higher affinity for the alpha-2-delta receptor and has linear pharmacokinetics. Siddall et al. (2006) published the results of a double blind randomized control trial evaluating the use of flexible dose pregabalin in the treatment of neuropathic pain in spinal cord injury. A total of 137 subjects with central neuropathic pain post spinal cord injury participated. The primary outcome was the VAS pain scale and secondary outcomes included sleep interference and anxiety scales. Seventy patients were randomized to receive pregabalin and 67 patients received placebo. At the end of the trial the pregabalin treated patients had significantly more pain relief. The pregabalin treated subjects also reported significantly improved sleep and anxiety. Side effects were mild and transient and included dizziness, drowsiness and edema (similar to gabapentin).

Arienti et al. (2011) compared treatment of pain in three groups: 1) pregabalin only group; 2) pregabalin and osteopathy group; 3) osteopathy group. The study found significant improvement in pain perception and pain relief in the combined pregabalin and osteopathy group compared to the other two groups (p<0.01). Further, relief of pain was faster in the combined group compared to the pregabalin and osteopathy only groups.

In a RCT conducted by Vranken et al. (2008) patients in the treatment group received escalating doses of pregabalin (150-600 mg daily), while those in the control group received a placebo. Subjects in the treatment group reported a significant decrease in pain (p<0.01), along with improvements in the EQ-5D VAS and utility scores (p<0.01), as well as the Bodily Pain subscale of the SF-36 (p<0.05), relative to the control group.

Cardenas et al. (2013) studied 220 patients with neuropathic pain post SCI they were randomized to 150-600mg of pregabalin (108 patients) vs Placebo (112) patients. The patients in the treatment group experienced significant improvements in all primary and key secondary outcomes including duration adjusted average change in pain, change in mean pain scores, percentage of patients with greater than 30% reduction in pain and reduction in pain related sleep interference scores compared to placebo. The improvements were seen as early as 1 week after initiation of treatment and lasted for the duration of the 17 week study. As with previous studies the medication was generally well tolerated, somnolence and dizziness were the most common side effects. This study provided class 1 evidence for the effectiveness of pregabalin 150mg to 600mg in the treatment of neuropathic pain post spinal cord injury.

**Lamotrigine**

Finnerup et al. (2002) studied the effects of lamotrigine on post SCI pain. Although the overall result showed no difference between placebo and lamotrigine, there was a significant reduction in pain in the incomplete spinal cord group.

**Levetiracetam**
Finnerup et al. (2009) conducted a randomized, double blind, crossover trial of levetiracetam in SCI individuals with pain. Participants were placed in either the levetiracetam or placebo group for 5 weeks and then crossed over after a 1 week washout period. This study found no significant difference between the levetiracetam and the placebo treatment group in improving pain intensity (p=0.46).

**Valproate**

In a double-blind cross-over study (n=20), Drewes et al. (1994) examined the effects of a 3 week treatment course of valproic acid on chronic central pain in individuals who had sustained a SCI. Overall, they found no significant differences between the control and treatment groups; however, there was a trend towards improvement in the treatment group.

<table>
<thead>
<tr>
<th>Table 21 Summary of Anticonvulsant Pain Treatment Post SCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
</tr>
<tr>
<td>Rintala et al. 2007</td>
</tr>
<tr>
<td>Levendoglu et al. 2004</td>
</tr>
<tr>
<td>Tai et al. 2002</td>
</tr>
<tr>
<td>To et al. 2002</td>
</tr>
<tr>
<td>Ahn et al. 2003</td>
</tr>
<tr>
<td>Putzke et al. 2002</td>
</tr>
<tr>
<td>Cardenas et al. 2013</td>
</tr>
<tr>
<td>Siddall et al. 2006</td>
</tr>
<tr>
<td>Vranken et al. 2008</td>
</tr>
<tr>
<td>Finnerup et al. 2002</td>
</tr>
<tr>
<td>Finnerup et al. 2009</td>
</tr>
<tr>
<td>Drewes et al. 1994</td>
</tr>
</tbody>
</table>

Note: *=in individuals with incomplete SCI

**Conclusion**

There is level 1a evidence (from two randomized controlled trials, and one case series, pre-post, and observational study; Levendoglu et al. 2004; Tai et al. 2002; To et al. 2002; Ahn et al. 2003; Putzke et al. 2002) that the Gabapentin and pregabalin improve neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Arienti et al. 2011) that combined pregabalin and osteopathy treatment improves pain post SCI.

There is level 4 evidence (from one pre-post study; Ahn et al. 2003) that the anticonvulsant Gabapentin is more effective when SCI pain is<6 months than >6 months.

There is level 1b evidence (from one randomized controlled trial; Finnerup et al. 2002) that lamotrigine improves neuropathic pain in incomplete spinal cord injury

There is level 1b evidence (from one randomized controlled trial; Finnerup et al. 2009) that Levetiracetam is not effective in reducing neuropathic pain post SCI.

There is level 2 evidence (from one randomized controlled trial; Drewes et al. 1994) that valproic acid does not significantly relieve neuropathic pain post SCI.
Tricyclic antidepressant drugs are thought to modulate pain by inhibiting the uptake of norepinephrine and serotonin in the CNS. Sandford et al. (1992) have suggested that the tricyclic antidepressants exert an analgesic effect by making more serotonin available in the CNS, thereby potentiating the inhibitory action of the dorsal horn of the spinal cord. Unfortunately, these medications are often sedating and produce a variety of anticholinergic side effects.

The partial effectiveness of tricyclic antidepressants (TCA) in some SCI patients with dysesthetic pain suggests that this drug is simply affecting the pain by treating the depression. Sandford et al. (1992) noted that pain and depression may be chemically linked. Depression can lower pain thresholds or pain tolerances thereby increasing the patient’s experience of pain. However, Max et al. (1987) were able to show that TCA had analgesic properties despite low doses or short treatment cycles with analgesic activity occurring independent of mood changes.

Davidoff et al. (1987b) reported trazodone’s lack of effectiveness in relieving pain in 19 SCI patients with chronic dysesthetic pain, using a double-blind placebo controlled trial. Trazodone reportedly selectively inhibits serotonin and norepinephrine uptake in a ratio of 25:1, and is thought to produce greater analgesia and less anticholinergic side-effects compared to non-selective agents such as amitriptyline.

### Table 22 Tricyclic Antidepressants in Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year; Country PEDro Score Research Design Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amitriptyline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rintala et al. 2007 USA PEDro=10 RCT N=38</td>
<td><strong>Population:</strong> SCI: Mean age=42.6 yr; Gender: males=20, females=2; Level of injury: paraplegia=7, tetraplegia=12; Severity of injury: AIS A-C=19, D=3; Time since injury=12.6 yr; Duration of pain=7.3 yr. Type of pain=Neuropathic <strong>Treatment:</strong> Patients were randomized into one of six groups: 1) gabapentin-amitriptyline-diphenhydramine (GAD; n=7); 2) GDA (n=6); 3) AGD (n=6); 4) ADG (n=6); 5) DGA (n=7); 6) DAG (n=6). Each drug was administered for 9 wk with one washout week before and after.</td>
<td>5. Amitriptyline was significantly more effective than diphenhydramine at 8 weeks, in subjects with high (≥ 10) baseline CESD-SF scores (p=0.035). 6. No significant difference was seen at 8 weeks in subjects with high (≥ 10) baseline CESD-SF scores in:  - Effectiveness of amitriptyline over gabapentin (p=0.061).  - Effectiveness of gabapentin over diphenhydramine (p=0.97). 7. Subjects with low (&lt;10) baseline</td>
</tr>
<tr>
<td>Author Year; Country PEDro Score Research Design Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>Cardenas et al. 2002 USA PEDro=9 RCT N=84</td>
<td>Population: Mean age=41 yr; Gender: males=80%, females=20%; Level of injury: cervical, lumbar; Severity of injury: AIS: A-D; Time since injury=169 mo. Type of pain=Neuropathic and musculoskeletal Treatment: Subjects with chronic pain randomized to a 6 wk course of amitriptyline or placebo 1-2 hr before bedtime. Outcome Measures: Average pain measure (scale 0-10), Short form McGill Pain Questionnaire (SF-MPQ), Brief Pain Inventory (BPI), Center of Epidemiologic Studies Depression Scale (CESD), Functional Independence Measure (FIM).</td>
<td>CESD-SF scores showed no significant difference among the medications. 1. There were no significant differences between the two groups at baseline and at the 6 wk time period for any of the measures except satisfaction with life which showed higher scores for those in the placebo group (p=0.004). 2. For those who remained on the two medications, it was noted that those in the amitriptyline group had significantly higher severity ratings for increased spasticity (p=0.005) than those in the control group.</td>
</tr>
<tr>
<td>Vranken et al. 2011 Netherlands PEDro=9 RCT N=48</td>
<td>Population: Age=53 yr. Type of pain=Neuropathic Intervention: Participants were randomized to one of two groups: flexible dose placebo who received 1-2 capsules a day or flexible dose duloxetine who received 1 to capsules of 60 mg daily. Outcome Measures: Visual Analogue Scale (VAS)</td>
<td>1. A two-point reduction on VAS in pain intensity was seen in the duloxetine group after 8 wk of treatment. 2. A decrease in pain was seen in the duloxetine group compared to the control group (p=0.05). 3. No significant between group differences were seen in SF-36.</td>
</tr>
<tr>
<td>Davidoff et al. 1987b USA PEDro=6 RCT Initial N=19; Final N=18</td>
<td>Population: Mean age=39 yr; Gender: males=16, females=2; Time since injury=49 mo. Type of pain=Neuropathic Treatment: Subjects underwent a 2 wk placebo lead-in period with a 6 wk randomization to 150 mg trazodone per day or placebo. Outcome Measures: McGill Pain Questionnaire (MPQ), Sternbach Pain Intensity (SPI), Zung Pain and Distress Index (PAD)</td>
<td>1. No significant differences were noted between the groups on MPQ, SPI, or PAD. 2. More subjects reported side effects in the experimental group (p&lt;0.05). 3. More subjects in the placebo group completed the 8 wk study (p&lt;0.01).</td>
</tr>
</tbody>
</table>

Note: AIS=ASIA Impairment Scale

**Discussion**

Tricyclic antidepressants are often recommended for the treatment of neuropathic pain following non-SCI causes. Therefore, it is important to study the use of tricyclic antidepressants in the treatment of post-SCI pain. Cardenas et al. (2002) reported no significant difference in randomized spinal cord injury patients receiving either amitriptyline or placebo given 1-2 hours before bedtime for a period of 6 weeks. Heilporn (1978) using combinations of melitracin and
TENS reported relief of pain in 8 of 11 SCI patients with dysesthetic pain. Vranken et al. (2011) found individuals receiving duloxetine reported clinically significant (>2 units on VAS) improvement on pain compared to those in a placebo control group. In an interesting study by Rintala et al. (2007), amitriptyline was no better than gabapentin in depressed and non-depressed subjects but was better than diphenhydramine for depressed subjects only.

Davidoff et al. (1987b), in a 6 week double-blind placebo-controlled trial, found that trazodone was ineffective at relieving pain in 18 SCI patients with chronic neuropathic pain.

Conclusion

**There is level 1b evidence (from one randomized controlled trial; Rintala et al. 2007) that amitriptyline is effective in the treatment of post-SCI neuropathic pain in individuals only when there is concomitent depression.**

**There is level 1b evidence (from one randomized controlled trial; Vranken et al. 2011) that duloxetine may improve neuropathic pain post SCI.**

**There is level 1b evidence (from one randomized controlled trial; Davidoff et al. 1987b) that trazodone does not reduce post-SCI neuropathic pain.**

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finnerup et al. 2005</td>
<td>Denmark</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>N=24</td>
<td><strong>Population:</strong> Type of pain=Neuropathic</td>
<td>1. In the total sample of patients, lidocaine reduced pain vs. placebo (p&lt;0.01).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Treatment:</strong> Subjects were initially divided into two groups: those with and without evoked pain. In this cross-over design, each group then was subdivided (experimental vs. controls) with experimental group receiving 5 mg of lidocaine infused over 30 min; controls received placebo.</td>
<td>2. Assessing those with and without evoked pain, lidocaine still superior to placebo at reducing pain (p&lt;0.01 and p&lt;0.048, respectively).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Outcome Measures:</strong> McGill Pain</td>
<td>3. More patients reported pain relief with at level and below-level pain while receiving lidocaine vs. placebo.</td>
</tr>
</tbody>
</table>

10.4 Anaesthetic Medications

Anaesthetic medication such as lidocaine and ketamine are sodium channel blockers and can be delivered by a number of routes. Ketamine is a non-competitive NMDA receptor antagonist that can be administered epidurally, intrathecally, and orally to treat neuropathic pain syndromes (Hocking & Cousins 2003).

Table 23 Anaesthetic Medications for Post-SCI Pain
<table>
<thead>
<tr>
<th>Author Year Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attal et al. 2000</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>N=16</td>
<td>Questionnaire (MPQ)</td>
<td>1. Effects of lidocaine on pain were greater than effects of placebo, starting at end of injection, and lasting for up to 45 min post injection (p&lt;0.05). 2. More people received pain relief with lidocaine than with placebo; however, relief waned by 60 min post injection. 3. Lidocaine reduced pain in 11 patients; and, in 6 of 12 patients, burning pain totally or partially relieved. 4. For those with brush-induced allodynia (n=8), lidocaine produced a reduction in intensity of allodynia 15 min post injection, and this lasted up to 30 min post injection.</td>
</tr>
<tr>
<td>Kvarnstrom et al. 2004</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>N=10</td>
<td>Questionnaire (MPQ)</td>
<td>1. VAS scores were significantly reduced in ketamine vs. the placebo group (p&lt;0.01). 2. Comparing lidocaine and placebo group, no significant difference noted (p=0.60). 3. Pain relief was not linked to altered temperature thresholds or other changes in sensory function.</td>
</tr>
<tr>
<td>Loubser &amp; Donovan 1991</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>N=21</td>
<td>Questionnaire (MPQ)</td>
<td>1. All 21 patients tolerated the injection (anaesthetics and placebo) well. 2. Negative placebo response was noted in 17 pts. Following lidocaine (n=13) patients showed a mean reduction in pain (p&lt;0.01) for an average of 123.1± 95.3 min. 3. The decrease in pain reduction following lidocaine was significant (p&lt;0.01) for the treatment group only.</td>
</tr>
<tr>
<td>Chiou-Tan et al. 1996</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>Initial N=15; Final N=11</td>
<td>Questionnaire (MPQ)</td>
<td>1. Visual analogue showed no significant differences for average pain levels over the past week and pain at time of test regardless of which medication (drug or placebo) subject was taking. 2. Results of the McGill Pain score also showed no significant differences between the groups. 3. No change in level of function for either group at any time of the study.</td>
</tr>
<tr>
<td>Kvarnstrom et al. 2004</td>
<td>PEDro=10</td>
<td>RCT</td>
<td></td>
<td>Questionnaire (MPQ)</td>
<td>1. VAS scores were significantly reduced in ketamine vs. the placebo group (p&lt;0.01). 2. Comparing lidocaine and placebo group, no significant difference noted (p=0.60). 3. Pain relief was not linked to altered temperature thresholds or other changes in sensory function.</td>
</tr>
<tr>
<td>Author Year</td>
<td>Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Eide et al. 1995</td>
<td>Norway</td>
<td>PEDro=7</td>
<td>RCT</td>
<td>N=9</td>
<td>Pain Scale: Visual Analogue Scale (VAS)</td>
</tr>
</tbody>
</table>

| | | N=10 | Pain Scale: Visual Analogue Scale (VAS) | | Pain Scale: Visual Analogue Scale (VAS) | |
| | | | | | | |

### Methods

- **Population:** Age=25-72 yr; Gender: males=8, females=1; Level of injury: cervical, thoracic; Severity of injury: AIS: A-D; Onset of pain: <6 mo post injury, Length of pain: 14-94 mo. Type of pain=Neuropathic

- **Treatment:** Ketamine hydrochloride, alfentanil or a placebo was given as combination of bolus and continuous intravenous infusions. The bolus dose was administered for 60 secs and the continuous intravenous infusion started simultaneously and was delivered by IVAC syringe pump. This lasted 17-21 min while the testing was performed.

- **Outcome Measures:** Visual Analogue Scale (VAS).

#### Outcome

1. Freidmann’s two-way analysis by ranks showed differences between the various treatments (p=0.005).
2. The effect of alfentanil and ketamine was also significant (p<0.01 and p<0.04 respectively).
3. No significant differences were noted between the actions of ketamine and alfentanil (Wilcoxon p=0.19).
4. Significant differences were noted between the treatment groups (p=0.008). It was also noted that allodynia was not more changed by ketamine than by alfentanil (Wilcoxon p=0.93).
5. Alfentanil reduced wind-up-like pain (p=0.014) compared to the placebo group. The effect of ketamine on wind-up-like pain was not significantly reduced (p=0.07).
6. A high correlation between the serum concentration of ketamine and the reduction of continuous pain (r=0.78, p<0.002) and the reduction of wind-up-like pain (r=0.83, p<0.002) was noted.

---

**Note:** AIS=ASIA Impairment Scale

---

### Discussion

**Lidocaine**

Given the severity of post-SCI pain, treatments such as lumbar epidural and subarachnoid infusions or anaesthetics are sometimes utilized and there is some evidence for these treatments. Loubser and Donovan (1991) conducted an RCT of 21 patients who were provided 2 separate lumbar subarachnoid injections of placebo and 5% lidocaine in dextrose. Following the lidocaine injection (n=13) there was a significant mean reduction in pain (p<0.01) for an average of 2 hours despite the fact that 8 patients showed no changes. However, this treatment provided short-term relief of pain only. The authors regarded the value of this treatment as more a diagnostic procedure than a therapeutic one.
Attal et al. (2000) reported on 15 patients who received lidocaine intravenously and experienced a greater reduction in pain than those who received placebo, with an effect lasting up to 45 minutes post injection, and a reduction in the intensity of brush-induced allodynia and mechanical hyperalgesia. In a RCT study by Finnerup et al. (2005) those patients who received lidocaine intravenously (n=24) in two treatment sessions 6 days apart reported significantly less pain than those who did not receive intravenous lidocaine.

Kvarnstrom et al. (2004) found no evidence for the effectiveness of intravenous lidocaine in reducing neuropathic pain when compared to placebo.

**Mexiletine**

Chiou-Tan et al. (1996) provided 15 SCI individuals with either oral mexiletine (an orally administered derivative of lidocaine) or placebo (150mg 3x daily) in a double-blind cross-over RCT. There was no appreciable improvement in pain severity, as measured either on a VAS or using the McGill Pain Questionnaire, within either group.

**Ketamine**

In one RCT of 10 subjects, Kvarnstrom et al. (2004) found ketamine was successful in reducing spontaneous neuropathic pain post SCI. Eide et al. (1995) in an RCT of intravenous ketamine hydrochloride (NMDA receptor antagonist), alfentanil (μ-opioid receptor agonist) or placebo were provided as combination of bolus and continuous intravenous infusions. There was a significant benefit to ketamine or alfentanil vs. placebo for allodynia. Alfentanil reduced wind-up pain compared to placebo but not ketamine overall; however, there was a high correlation between the serum concentration of ketamine and the reduction in continuous pain and wind-up pain. The effects of ketamine and alfentanil were significant when compared to placebo.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>N</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finnerup et al. 2005</td>
<td>RCT</td>
<td>24</td>
<td>Lidocaine</td>
<td>+</td>
</tr>
<tr>
<td>Attal et al. 2000</td>
<td>RCT</td>
<td>16</td>
<td>Lidocaine</td>
<td>+</td>
</tr>
<tr>
<td>Kvarnstrom et al. 2004</td>
<td>RCT</td>
<td>10</td>
<td>Lidocaine</td>
<td>-</td>
</tr>
<tr>
<td>Loubser &amp; Donovan 1991</td>
<td>RCT</td>
<td>21</td>
<td>Lidocaine</td>
<td>+</td>
</tr>
<tr>
<td>Chiou-Tan et al. 1996</td>
<td>RCT</td>
<td>15</td>
<td>Mexiletine</td>
<td>-</td>
</tr>
<tr>
<td>Kvarnstrom et al. 2004</td>
<td>RCT</td>
<td>10</td>
<td>Ketamine</td>
<td>+</td>
</tr>
<tr>
<td>Eide et al. 1995</td>
<td>RCT</td>
<td>9</td>
<td>Ketamine</td>
<td>+</td>
</tr>
</tbody>
</table>

**Conclusion**

*There is level 1b evidence (from one randomized controlled trial; Loubser & Donovan 1991) that Lidocaine delivered through a subarachnoid lumbar catheter provides short-term relief of pain greater than placebo.*

*There is level 1a evidence (from two randomized controlled trials; Kvarnstrom et al. 2004; Eide et al. 1995) that intravenous Ketamine significantly reduces allodynia when compared to placebo.*

*There is level 1b evidence (from one randomized controlled trial; Chiou-Tan et al. 1996) that mexiletine (a derivative of lidocaine) does not improve SCI dysesthetic pain when compared to placebo.*
10.5 Antispasticity Medications

Herman et al. (1992) note that baclofen, an α-aminobutyric acid (GABA)\textsubscript{B} receptor agonist, acts to suppress spasticity in SCI patients centrally within the spinal cord itself. GABA is known to be involved in several analgesics pathways (Sawynok 1987) and experimentally induced allodynia has been shown to be suppressed by baclofen (Henry 1982). However, baclofen, by treating spasticity, may reduce the musculoskeletal pain associated with spasticity. Continuous intrathecal infusion of baclofen can be effective, when oral baclofen is ineffective, in further reducing post-SCI spasticity and/or pain (dysesthetic, musculoskeletal, neurogenic; Boviatis et al. 2005; Herman & D'Luzansky 1991; Penn & Kroin 1987; Plassat et al. 2004). For an in-depth discussion of intrathecal baclofen and its effects on spasticity in SCI, please refer to the Spasticity chapter.

Table 25 Antispastic Medications for Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baclofen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boviatis et al. 2005</td>
<td>Greece</td>
<td>Case Series</td>
<td>Initial N=22; Final N=21</td>
<td>Population: MS, SCI (N=7): Level of injury: C4 to T11. Results were presented by etiology. Treatment: Subjects were implanted with an intrathecal baclofen infusion pump delivering a continuous flow at a fixed rate of bolus intrathecal Baclofen. Outcome Measures: Barthel index scale, Ashworth scale and Penn spasm scale, self-assessment pain scale.</td>
<td>1. The self-assessment pain scale revealed a limited improvement in pain (p=0.0941).</td>
<td></td>
</tr>
<tr>
<td>Plassat et al. 2004</td>
<td>France</td>
<td>Case Series</td>
<td>Initial N=41; Final N=37</td>
<td>Population: SCI (N=17), MS and cerebral spasticity - spasticity of spinal cord origin, N=33) Treatment: Intrathecal Baclofen pump implantation. Those suffering from neuropathic pain received co-administration of morphine or clonidine. Outcome Measures: Visual Analogue Scale (VAS), Satisfaction Score for locomotion, pain, sleep, and Ashworth Scale.</td>
<td>1. Of the 25/40 patients suffering pain before ITB (Intrathecal Baclofen), 80% noted 25% improvement in pain and 40% noted 30-50% improvement. Twenty percent reported no change.</td>
<td></td>
</tr>
<tr>
<td>Loubser &amp; Akman 1996</td>
<td>USA</td>
<td>Pre-post</td>
<td>N=16</td>
<td>Population: Age=21-63 yr; Gender: males=15, females=1; Severity of injury: Frankel classification: A-C; Type of pain: neurogenic=6, musculoskeletal=6, neuropathic and musculoskeletal pain=3. Treatment: Intrathecal Baclofen pump implantation. Outcome Measures: Visual Analogue Scale (VAS).</td>
<td>1. The majority (75%) of patients reported chronic pain prior to the procedure. 2. No significant differences were noted on VAS at 6 mo and 12 mo following pump implantation. 3. For those with neurogenic pain symptoms, ANOVA revealed a non-significant effect of intrathecal baclofen on pain at both 6 and 12</td>
<td></td>
</tr>
</tbody>
</table>

Lidocaine through a subarachnoid lumbar catheter and intravenous Ketamine improve post-SCI neuropathic pain short term. Mexilitene does not improve SCI dysesthetic pain.
Motor Point Phenol Block

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uchikawa et al. 2009</td>
<td>Japan</td>
<td>Case Series</td>
<td>N=7</td>
<td></td>
<td></td>
<td>Significant improvement was observed in passive ROM of shoulder flexion, abduction and external rotation and shoulder pain - VAS (p&lt;0.05).</td>
</tr>
</tbody>
</table>

Population: Mean age=55.8 yr; Gender: males=6, females=1; Level of injury: C; Severity of injury: AIS A=2, C=1, D=4.
Treatment: A teflon coated needle and a weak electric stimulation was used to localize a motor point on the anterior surface of the scapula. Phenol was injected into the point where the strongest muscle contraction was observed. Assessments were made before and 24 hr post injection.
Outcome Measures: Visual Analogue Scale (VAS), Ashworth Scale, flexion, abduction, rotation.

1. Significant improvement was observed in passive ROM of shoulder flexion, abduction and external rotation and shoulder pain - VAS (p<0.05).
2. No significant improvement was seen in the modified Ashworth scale ratings and the manual muscle test ratings for flexion, abduction and external rotation.

Botulinum Toxin

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marciniak et al. 2008</td>
<td>USA</td>
<td>Case Series</td>
<td>N=28</td>
<td></td>
<td></td>
<td>Improvement was seen post-injection in ambulation (56%), positioning (71%), upper-extremity function (78%), hygiene (66.6%), and pain (83.3%).</td>
</tr>
</tbody>
</table>

Population: SCI; Mean age=48 yr; Severity of injury: AIS A=5, B-D=23; Cause of injury: traumatic=3, falls=8, gunshot wounds=1, diving=3, knife wound=1, blunt trauma=1.
Treatment: Botulinum toxin (BTX) type A injection for focal spasticity control.
Outcome Measures: Improvement in ambulation, positioning, upper-extremity function, hygiene, pain.

1. Improvement was seen post-injection in ambulation (56%), positioning (71%), upper-extremity function (78%), hygiene (66.6%), and pain (83.3%).
2. The effectiveness of BTX injections was not influenced by early use of BTX injections (less than a year after onset of symptoms) vs. late use.
3. Improvement in those with upper arm compared to lower arm injections was similar.
4. SCI completeness did not affect improvement.

Discussion

Baclofen

Boviatsis et al. (2005) and Plassat et al (2004) presented case series data that reflected improvements in self-reported pain ratings after intrathecal baclofen administration. Herman et al. (1992) in a RCT found that intrathecal baclofen significantly suppressed the dysesthetic (burning) pain among 6 of the 7 subjects (p<0.001). Only one of the placebo patients noted the dysesthetic pain was abolished. Intrathecal baclofen did not have a significant impact on pinch induced pain. Therefore, in this study, intrathecal baclofen appeared to have an impact on post-SCI dysesthetic pain in addition to treating the spasticity. Loubser and Akman (1996) performed a before and after study of implanted Baclofen infusion pumps provided for spasticity. Twelve (12) of 16 patients described pre-existing chronic pain but there was no significant difference in
the VAS neurogenic pain symptoms at 6 and 12 months (p=0.26) while musculoskeletal pain symptoms and pain severity decreased in conjunction with control of spasticity in 5 of 6 patients. In this study, it appeared musculoskeletal pain was reduced more with intrathecal baclofen, presumably by reducing spasticity.

Hence, it would appear that intrathecal baclofen improves chronic post-SCI pain but the actual mechanism has not been adequately established. There is evidence that baclofen infusion pumps may be helpful for both neuropathic and musculoskeletal pain after SCI (Loubser & Akman 1996). However, studies have shown that intrathecal baclofen only reduces SCI pain when pain is related to muscle spasms (Coffey et al. 1993; Meythaler et al. 1992). Suppression of central pain through baclofen antagonism of substance P has been postulated (Herman et al. 1992).

**Motor Point Phenol Block**

In a case series, Uchikawa et al. (2009) followed 7 spinal cord injury individuals with spastic shoulder pain underwent a motor point phenol block procedure. A significant improvement in VAS shoulder pain was seen post injection (p<0.05).

**Botulinum Toxin**

Marciniak et al. (2008) treated 29 SCI patients with Botulinum toxin type A injections to treat focal spasticity. Pain was improved by 83.3%.

**Conclusion**

There is conflicting level 4 evidence (from two case series studies and one pre-post study; Boviatsis et al. 2005; Plassat et al. 2004; Loubser & Akman 1996) that intrathecal baclofen reduces dysesthetic pain post-SCI.

There is level 4 evidence (from one pre-post study; Loubser & Akman 1996) that intrathecal baclofen reduces musculoskeletal pain post-SCI in conjunction with spasticity reduction.

There is level 4 evidence (from one case series study; Uchikawa et al. 2009) that motor point phenol block is effective in reducing short term spastic shoulder pain post SCI.

There is level 4 evidence (from one case series study; Marciniak et al. 2008) that local botulinum toxin injections to treat focal spasticity reduces pain.

| Intrathecal Baclofen improves musculoskeletal pain post SCI and may help dysesthetic pain related to spasticity. |
| Motor point phenol block reduces spastic shoulder pain. |
| Botulinum toxin injections for focal spasticity improves pain. |
10.6 Opioids for Post-SCI Pain

To date there are few research studies examining opioids in the treatment of SCI pain. There is a substantial body of research investigating the benefits of opioid analgesics in the treatment of non-cancer chronic pain and some of those studies examined the impact of opioids on neuropathic pain. There are no studies employing opioid analgesics in post-SCI pain. Furlan et al. (2006) conducted a meta-analysis of effectiveness and side-effects of opioid analgesics for chronic non-cancer pain. Their meta-analysis found that opioids reduced pain and improved functional outcomes when compared to placebo for both nociceptive and neuropathic pain syndromes. Strong opioids (oxydone and morphine) were significantly superior to naproxen and nortriptyline for pain relief but not functional outcomes. Weak opioids (propylene, tramadol and codeine) did not significantly do better than NSAIDS or tricyclic anti-depressants for either pain relief or functional outcomes (Furlan et al. 2006). The authors found that clinically, only constipation and nausea were significantly more common with opioids. The big concern with opioids is of course addiction or opioid abuse. Unfortunately, as Furlan et al. (2006) notes in their meta-analysis, the existing randomized trials were not designed to evaluate addiction.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attal et al. 2002</td>
<td>France</td>
<td>PEDro=10</td>
<td>RCT</td>
<td>15</td>
<td>Population: SCI: Mean age=54.9 yr; Gender: males=6, females=9; Mean duration of pain=5 yr. Treatment: Initially, patients received intravenous morphine titrated up to the maximal tolerated dosage using successive bolus injections of 2 mg morphine every 10 minutes. Double blind phase began 3 wk after titration phase. Outcome Measures: Spontaneous pain, tactile allodynia, psychophysical measurements, mechanical detection and pain thresholds, thermal detection and pain.</td>
<td>1. Spontaneous pain scores decreased immediately after the end of the infusion of morphine and placebo for up to 120 min in both groups. 2. The effects of the morphine did not differ significantly from those who were given the placebo post injection. 3. Those who reported pain relief from the treatment was higher (3x) after the morphine than after the placebo was given from 15-60 min post injection. 4. Burning pain was weakened by the morphine in seven patients and by placebo in four patients. 5. When looking at the effects of morphine on mechanical allodynia it could be seen that the morphine produced a reduction in intensity. The saline treatment did not have an effect. 6. Morphine only significantly reduced dynamic mechanical allodynia (p&lt;0.01).</td>
<td></td>
</tr>
<tr>
<td>Norrbrink &amp; Lundeborg</td>
<td>2009</td>
<td>Sweden</td>
<td>PEDro=8</td>
<td>RCT</td>
<td>35</td>
<td>Population: Mean age=51.3 yr; Gender: males=28, females=7; Level of injury: tetraplegia=16, paraplegia=19; Type of pain=neuropathic. Treatment: Patients were randomized in a 2:1 ratio (tramadol/placebo) and treatment was administered for 4 wk. Both patients and staff were blind to the treatments. Each patient was given 50 mg tramadol or placebo 3x/day. The daily dose was increased by one tab for 5 5</td>
<td>1. Significant differences were seen in between group pain ratings (p&lt;0.05). 2. Patient Global Impression of Change rating was significantly higher in the tramadol group than the control group. 3. Significant improvements were seen in ratings of anxiety, global life satisfaction and sleep quality (p&lt;0.05). 4. No significant changes were seen in</td>
</tr>
<tr>
<td>Author Year Country</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eide et al. 1995 Norway</td>
<td>days to a maximum dose of 8 tab. <strong>Outcome Measures</strong>: Patient Global Impression of Change; Multidimensional Pain Inventory</td>
<td>pain pleasantness, depression, or on the MPI scales pain interference, perceived life control, affective distress or social support.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population: Age=25-72 yr; Gender: males=8, females=1; Level of injury: cervical, thoracic; Severity of injury: AIS: A-D; Onset of pain: &lt;6 mo post injury, Length of pain: 14-94 mo. <strong>Treatment</strong>: Ketamine hydrochloride, alfentanil or a placebo was given as combination of bolus and continuous intravenous infusions. The bolus dose was administered for 60 sec and the continuous intravenous infusion started simultaneously and was delivered by IVAC syringe pump. This lasted 17-21 min while the testing was performed. <strong>Outcome Measures</strong>: Visual Analogue Scale (VAS).</td>
<td>1. Friedmann’s two-way analysis by ranks showed differences between the various treatments (p=0.005). 2. The effect of alfentanil and ketamine was also significant (p&lt;0.01 and p&lt;0.04 respectively). 3. No significant differences were noted between the actions of ketamine and alfentanil (Wilcoxon p=0.19). 4. Significant differences were noted between the treatment groups (p=0.008). It was also noted that allodynia was not more changed by ketamine than by alfentanil (Wilcoxon p=0.93). 5. Alfentanil reduced wind-up-like pain (p=0.014) compared to the placebo group. The effect of ketamine on wind-up-like pain was not significantly reduced (p=0.07). 5. A high correlation between the serum concentration of ketamine and the reduction of continuous pain (r=0.78, p&lt;0.002) and the reduction of wind-up-like pain (r=0.83, p&lt;0.002) was noted.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barrera-Chacón et al. 2010 Spain</td>
<td><strong>Population</strong>: Age: 46.4 yr, Severity of injury: AIS A=27, B=1, C=10. <strong>Intervention</strong>: Participants were provided with oxycodone treatment for neuropathic pain. <strong>Outcome Measures</strong>: Visual Analogue Scale (VAS)</td>
<td>1. Pain intensity significantly decreased after 3 mo of oxycodone treatment, p&lt;0.001. 2. Improvement in sleep and physical activity levels was also seen. 3. 83% of individuals were taking adjunct anticonvulsant treatment. 6. The most common side effect included constipation (33%).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Discussion**

Attal et al. (2002) found the intravenous morphine titrated to maximal tolerated dosage, significantly reduced dynamic mechanical allodynia but not necessarily spontaneous or burning pains. Oral opioids remain untested in this population.

Norrbrink and Lundeberg (2009) conducted a double-blind RCT to assess the efficacy of tramadol in 35 SCI individuals diagnosed with at- or below- level neuropathic pain. The authors reported significant differences between the two group pain ratings (p<0.05). Tramadol was also found to be effective in improving anxiety, global life satisfaction and sleep quality in individuals with post SCI pain (p<0.05). However, no significant improvement was seen in pain unpleasantness and depression levels.
Eide et al. (1995) randomly assigned individuals with chronic SCI pain into three groups receiving ketamine hydrochloride, alfentanil (μ-opioid receptor agonist) or placebo treatment. The study found alfentanil and ketamine effectively reduced SCI pain compared to placebo treatment (p<0.04, p<0.01); however no difference was seen between the two treatments in overall pain. Alfentanil significantly reduced wind up like pain while ketamine did not.

In a pre-post study, Barrera-Chacón et al. (2010) found oxycodone significantly decreased pain intensity and improved sleep (p<0.001) among individuals experiencing neuropathic pain post SCI. These effects were seen mostly in combination with anticonvulsant treatment.

Conclusion

There is level 1b evidence (from one randomized controlled trial; Attal et al. 2002) that intravenous morphine significantly reduces mechanical allodynia more than placebo.

There is level 1b evidence (from one randomized controlled trial; Norrbrink & Lundeberg 2009) that tramadol is effective in reducing neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Eide et al. 1995) that alfentanil reduces overall post SCI pain.

There is level 1b evidence (from one randomized controlled trial; Eide et al. 1995) that alfentanil is more effective at reducing wind up like pain than ketamine.

There is level 4 evidence (from one pre-post study; Barrera-Chacon et al. 2010) that oxycodone and anticonvulsants may be effective in improving SCI neuropathic pain.

10.7 Cannabinoids in Post-SCI Pain

Wade et al. (2003) note that delta-9-tetra hydrocannabinol (THC) and other cannabinoids have been shown to improve both tremor and spasticity in animal models of multiple sclerosis supported by anecdotal reports that cannabis relieves some of the troublesome symptoms of multiple sclerosis and spinal cord injury (Baker et al. 2000; Consroe et al. 1997; Dunn & Davis 1974; Martyn et al. 1995; Meinck et al. 1989; Petro & Ellenberger 1981; Ungerleider et al.1987). There is a clinical impression that marijuana smoking is very common among patients post-SCI;
however, there are social and legal implication to its use and medical concerns about smoking as a delivery system.

Table 27 Cannabinoids and Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rintala et al. 2010</td>
<td>USA</td>
<td>PEDro=5</td>
<td>RCT</td>
<td>N=7</td>
<td>Population: Mean age: 50.1 yr. Severity of injury: AIS A=4, B=1, D=2. Level of injury: paraplegia=4, tetraplegia=3. Mean time since injury was 21.9 yr. Type of pain=Neuropathic. Treatment: Participants were randomized into two groups: 1) 5 mg dronabinol titrated every third day (max 20 mg/day); 2) 25 mg diphenhydramine day one then titrated up to 75 mg/day. Participants remained in a seven day stabilization phase once titration was complete and then a 28 day maintenence phase. Next participants completed a nine day weaning-off phase followed by a seven day washout period. Each participant then crossed over to the other group. Outcome Measures: Brief Pain Inventory (BPI)</td>
<td>1. Pain intensity was not significantly different between the dronabinol and diphenhydramine groups. 2. No significant difference was seen in side effects between the groups. 1. Most common side effects included dry mouth, constipation, fatigue and drowsiness.</td>
</tr>
<tr>
<td>Hagenbach et al. 2007</td>
<td>Switzerland</td>
<td>PEDro=4</td>
<td>RCT</td>
<td>N=13</td>
<td>Population: SCI (N=15): Age=29-66 yr; Gender: males=11, females=2; Level of injury: C4-T11; Severity of injury: AIS: A,B,C,D Type of pain=spastic. Treatment: Phase 1-2: Patients received 10 mg oral tetra hydrocannabinol (THC) on day one. Dose titration began on day two until the maximum tolerated dose or treatment aim was achieved and maintained for 6 wk. Phase 3: In a double blind manner, SCI patients from phase 1 of the study were randomly assigned to either maximum oral THC doses (6 participants) or placebo doses (7 participants) for 6 weeks. Pain Scale: Self ratings</td>
<td>1. Significant improvement in pain was seen on day one compared to baseline measures (p=0.047). 2. No significant improvement in pain post SCI was seen compared to placebo on day 8 and 43. 3. Individuals in the oral THC group showed no significant difference in mood or attention compared to the placebo group or to baseline.</td>
</tr>
</tbody>
</table>

Note: AIS=ASIA Impairment Scale

Discussion

Rintala et al. (2010) examined the effect of dronabinol versus an active control (diphenhydramine) on pain post SCI. The study found no significant difference on pain intensity between the two treatments.

Hagenbach et al. (2007) conducted a study examining primarily the effectiveness of THC in improving spasticity and secondarily, in improving pain with SCI individuals. In the first phase of the study, 22 individuals received 10mg of oral THC which was then dose titrated until maximum tolerance or treatment dose was reached for 6 weeks. The study found a significant reduction in the pain of SCI individuals post treatment (p=0.047). The third phase of the study involved a double blind randomized control trial which included 13 of the previously mentioned individuals
receiving either individual maximum treatment dosage previously determined or a placebo dose. In this phase, Hagenbach et al. (2007) found individuals in the treatment group had no significant pain reduction compared to those in the placebo group.

Given that marijuana has anecdotally been thought to have benefits for post-SCI pain, Wade et al. (2003) conducted an RCT of sublingual 2.5 mg THC and/or cannabidiol and found that it helped to reduce pain, muscle spasm, spasticity and sleep in a group of largely multiple sclerosis patients with neuropathic pain. It is of note that only a small percentage of the patients in this study had spinal cord injuries hence did not meet inclusion criteria. Cannabinoids are a promising treatment, which would benefit from other studies.

Conclusion

*There is conflicting level 2 evidence (from one randomized controlled trial; Hagenbach et al. 2007) for the use of delta-9-tetrahydrocannabinol in reducing spastic pain in SCI individuals.*

*There is level 2 evidence ((from one randomized controlled trial; Rintala et al. 2010) that dronabinol is not effective in reducing pain intensity post SCI.*

| Cannabinoids are a potential new treatment for post-SCI pain in need of further study. |
| Dronabinal is not effective in reducing pain post SCI. |

**10.8 Clonidine for Post-SCI Pain**

Clonidine is an alpha-2 adrenoceptor agonist which has been shown to activate spinal receptors that reduce responses to painful stimuli (Yaksh 1985). Ackerman et al. (2003) note that clonidine inhibits nociceptive impulses by activating alpha-2 adrenoceptors in the dorsal horn of the spinal cord (Rainov et al. 2001). The anti-nociceptive effects of clonidine are thought to be mediated via inhibitory interaction with pre- and post-synaptic primary afferent nociceptive projections in the dorsal horn (Osenbach & Harvey 2001) and possibly by inhibition of substance P release (Ackerman et al. 2003; Hassenbusch et al. 1999). Ackerman et al. (2003) noted selective alpha-2 adrenergic antagonists (e.g. Yohimbine) have been shown to reverse clonidine-induced analgesia (Osenbach & Harvey 2001). Teasell and Arnold (2004) were able to show that venous alpha-adrenoceptor hyper-responsiveness was present in patients with RSD, in diabetic peripheral neuropathy (Arnold et al. 1993) and below the level of lesion in quadriplegics (Arnold et al. 1995). They speculated that this alpha-adrenoceptor hyper-responsiveness was in fact due to alpha-2 adrenoceptor dysfunction leading to overstimulation of the post-synaptic alpha-1 adrenoceptor peripherally. This would fit with the observation that clonidine reduces pain post-SCI below the level of the lesion, presumably through its alpha-2 adrenoceptor agonist function.

Ackerman et al. (2003) noted that clonidine may be useful for patients who are non-responsive to opioids. Clonidine appears to work synergistically with opioids to provide pain relief (Osenbach & Harvey 2001; Plummer et al. 1992; Siddall et al. 2000; Tallarida et al. 1999).

**Table 28 Clonidine for Treatment of SCI Pain**
<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siddall et al. 2000</td>
<td>Australia</td>
<td>Population: Age=26-78 yr; Neuropathic pain: 13 had below level neuropathic pain, 4 at level of neuropathic pain, 3 had both types of pain. Treatment: Placebo, morphine or Clonidine was delivered via catheter into lumbar intrathecal space. The subjects were first given either: 2. 1 mg morphine, 50-100 mcg of Clonidine or placebo. Dosage was increased if the subject had no side effects and no pain relief. Subjects could receive up to 1.5 times the initial drug dosage if necessary. Once the subject received satisfactory pain relief or side effects from the drug they were on they were given a mixture of morphine and Clonidine. Outcome Measures: Numerical pain rating scale, numerical pain relief score, a verbal pain rating and a nausea scale and sedation scores were recorded.</td>
<td>1. The administration of morphine or clonidine resulted in a mean reduction in pain levels but this was not statistically significant compared to the effect of placebo. 2. When the mixture of morphine and clonidine was administered there was a significant reduction in pain when compared to those on placebo (p=0.0084).</td>
</tr>
<tr>
<td>Uhle et al. 2000</td>
<td>Germany</td>
<td>Population: Age=34-77 yr; Gender males=4, females=6; Time since injury=1-10 yr. Treatment: Subjects, once implanted with a medical pump, were originally given 3 mL of saline followed by 1 mL of morphine, this was followed by a second dose of morphine (0.02 mg) provided no side effects or benefits were noted. This was followed by Clonidine (30 ug in 1 mL) and then depending on side effects a final dose of Clonidine (50 ug in 1 mL). After each drug administration the catheter was flushed with saline. Outcome Measures: Not specified.</td>
<td>1. Subjects reported a good to excellent pain reduction following the administration of Clonidine administration. 2. After Clonidine bolus subjects experienced an optimum pain reduction. Average dose of Clonidine was initially 53 ug/day and this decreased (or stabilized) to 44 ug/day.</td>
</tr>
</tbody>
</table>

**Discussion**

Siddall et al. (2000) in a cross-over RCT of 20 subjects with post-SCI neuropathic pain received intrathecal morphine, clonidine or placebo at the lumbar level. Once the subjects received satisfactory pain relief or drug side effects they were given a mixture of clonidine and morphine. Morphine or clonidine showed a trend in pain reduction, which was not statistically significant but when the combination of morphine and clonidine was administered there, was a significant reduction in pain. Siddall et al. (2000) did postulate that by administering half the effective minimum dose of clonidine and morphine together resulted in a synergistic addictive effect above the simple summing up of each drug in isolation. In a study by Uhle et al. (2000) 10 patients were given morphine followed by clonidine via a medical pump. Patients given clonidine experienced a good to excellent reduction in their pain.

**Conclusion**

*There is level 1b evidence (from one randomized controlled trial; Siddall et al. 2000) that intrathecal clonidine alone does not provide pain relief greater than placebo.*
There is level 2 evidence (from one prospective controlled trial; Uhle et al. 2000) that the combination of intrathecal morphine and clonidine provides pain relief greater than placebo.

Intrathecal Clonidine alone does not appear to provide pain relief although it may be helpful in combination with Intrathecal Morphine.

10.9 Topical Capsaicin
Capsaicin is an active alkaloid in hot peppers. It has been successfully used to reduce pain in herpes zoster, diabetic neuropathy and post-mastectomy pain syndrome (Sandford & Benes 2000). It works as an inhibitor of substance P.

Table 29 Topical Capsaicin in Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Country</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandford &amp; Benes 2000</td>
<td>USA</td>
<td>Case Series</td>
<td>N=8</td>
<td></td>
<td>Population: SCI; Age=18-66 yr; Gender: males=6, females=2; Level of injury: C6-L5; Severity of injury: complete=4, incomplete=4; Cause of injury: MVA=3, GSW=3, fall=1, aneurysm repair=1. Treatment: Patients who underwent topical capsaicin therapy to reduce pain were retrospectively reviewed. Outcome Measures: Reduction in pain.</td>
<td>1. Patients showed improvement in pain in 1-2 wk of topical capsaicin therapy. 2. Two patients showed long-term efficacy for over 2 yr.</td>
</tr>
</tbody>
</table>

Discussion
Topical capsaicin was used to treat radicular post-SCI pain for 1-2 weeks (Sandford & Benes 2000). Patients showed improvement in pain and 2 of the 8 patients were still improved for over 2 years.

Conclusion
There is level 4 evidence (from one case series study; Sandford & Benes 2000) that topical capsaicin reduces post-SCI radicular pain.

Topical capsaicin reduces post-SCI radicular pain.

11.0 Surgical Interventions

11.1 Spinal Cord Stimulation
Spinal cord stimulation has been used to try to treat intractable pain. The procedure is both expensive and invasive.
Table 30 Spinal Cord Stimulation Post SCI

<table>
<thead>
<tr>
<th>Author Year Country PEDro Score Research Design Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cioni et al. 1995 Italy Case Series N=25</td>
<td><strong>Population:</strong> Age=33-76 yr; Gender: males=19, females=6; Time since injury=1-39 yr. Type of pain=Neuropathic and musculoskeletal <strong>Treatment:</strong> An epidural electrode was inserted percutaneously over the posterior columns of the spinal cord. Spinal cord stimulation was performed with the following parameters: 85 cycles/sec, duration of 210 msec and varied intensity for comfortable parasthesias 30 min every 3 hr during the day. Mean follow-up was 37.3 mo. <strong>Outcome Measures:</strong> Pain relief.</td>
<td>1. During stimulation, 22 patients reported parasthesias overlapping the painful area. 2. 9 patients enjoyed 50% pain relief at the end of the test period. No pain relief was found in 3 of the patients. No statistical results reported.</td>
</tr>
</tbody>
</table>

Discussion

Cioni et al. (1995) reported inserting epidural electrodes over the posterior columns of the spinal cord to allow for spinal cord stimulation. During spinal cord stimulation, 22 patients reported paraesthesia overlapping the painful area. Nine patients reported 50% pain relief and 3 patients experienced no pain relief.

Conclusion

*There is level 4 evidence (from one case series study; Cioni et al. 1995) that spinal cord stimulation improves post-SCI pain.*

Spinal cord stimulation may improve post-SCI neuropathic and musculoskeletal pain.

11.2 Dorsal Longitudinal T-Myelotomy for Pain Management Post-SCI

Table 31 Dorsal Longitudinal T-Myelotomy Post-SCI Pain

<table>
<thead>
<tr>
<th>Author Year Country PEDro Score Research Design Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Livshits et al. 2002 Germany/Israel Case Control N=40</td>
<td><strong>Population:</strong> Type of pain=spastic <strong>Treatment:</strong> Individuals with SCI underwent one of two different surgical procedures: longitudinal T-myelotomy using the Bischof II technique (n=20), or longitudinal myelotomy en croix (Pourpre procedure) (n=20). <strong>Outcome Measures:</strong> Short form McGill Pain Questionnaire (SF-MPQ); Visual Analogue Scale (VAS)</td>
<td>1. All individuals (regardless of surgical procedure) reported some pain relief. 2. The Pourpre procedure appeared better than the Bischof II procedure at relieving pain, as measured by VAS and SF-MPQ (in the immediate and long term). 3. By yr 5 and yr 10, individuals in both groups reported a return of motor spasticity.</td>
</tr>
</tbody>
</table>
Discussion

Livshits et al. (2002) conducted a case control study comparing two approaches of dorsal longitudinal T-myelotomy (i.e., Pourpre vs. Bischof II) with respect to their effectiveness in reducing pain and spasticity in people with SCI, initially refractory to more conservative approaches (N=40). Systematic follow-up assessments at 6 months, 5 and 10 years were conducted. In this study, significant pain reduction was obtained with either of these surgical techniques, as measured using scores obtained from the Short Form – McGill Pain Questionnaire (Short form McGill Pain Questionnaire), the Present Pain Intensity scale, and a visual analog scale, but this appeared to be more notable with the Pourpre versus the Bischof II procedure.

Conclusion

*There is level 3 evidence (from one case control study; Livshits et al. 2002) to support the use of dorsal longitudinal T-myelotomy procedures, in particular Pourpre’s technique, to reduce spastic pain post SCI.*

Dorsal longitudinal T-myelotomy procedures reduce pain post SCI.

11.3 Dorsal Rhizotomy

Dorsal rhizotomy is a procedure where the sensory roots are divided either intradurally or extradurally. According to Nashold (1991) a single one or two level root rhizotomy may be appropriate when the pain is localized as in those patients with paraparesis and single root pain. Moreover, Nashold (1991) reported the Dorsal Root Entry Zone (DREZ) procedure was more likely to be successful in these patients.

**Table 32 Dorsal Root Entry Zone Procedure Post-SCI Pain**

<table>
<thead>
<tr>
<th>Author Year Country</th>
<th>Authors</th>
<th>PEDro Score</th>
<th>Research Design</th>
<th>Total Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chun et al. 2011</td>
<td>Korea</td>
<td>Pre-post</td>
<td>N=38</td>
<td>Population: Age: 49 yr, Level of injury: T=5, Conus Medullaris=33. Severity of Injury: AIS A=27; B11.</td>
<td>Treatment: MDT was performed according to Sindou's technique Outcome Measures: Visual Analogue Scale (VAS)</td>
<td>1. Overall patients achieved good (79.0%), fair (10.5%) and poor (10.5%) poor pain relief. 2. Good pain relief was achieved in 82.5% of those with mechanical pain and 100% with combined pain, vs. 20% with thermal pain 3. Good pain relief was achieved in those with diffuse pain (73.3%) and segmental pain (82.6%) 4. Good pain relief was achieved in those with intermittent pain (78.2%) and continuous pain (80.0%)</td>
</tr>
<tr>
<td>Falci et al. 2002</td>
<td>USA</td>
<td>Prospective Controlled Trial</td>
<td>N=41</td>
<td>Population: Neuropathic pain Intervention: The first nine patients were placed in group 1 and the next 32 in group 2. Individuals in group 1 underwent Dorsal Root Entry Zone (DREZ) microcoagulation using recorded</td>
<td>2. Seven patients in the first group achieved at least 50% pain relief post treatment while five patients achieved 100%. 3. In the second group, 84% of patients reported 100% pain relief post</td>
<td></td>
</tr>
<tr>
<td>Author Year Country</td>
<td>PEDro Score</td>
<td>Research Design</td>
<td>Total Sample Size</td>
<td>Methods</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Spasic et al. 2002</td>
<td></td>
<td>Case series</td>
<td>N=26</td>
<td>spontaneous neuroelectrical hyperactivity in DREZ as a guide. While the second group underwent DREZ microcoagulation using the above recorded spontaneous neuroelectrical hyperactivity in the DREZ as well as recorded evoked hyperactivity during TCS of the DREZ. <strong>Outcome Measures</strong>: Visual Analogue Scale (VAS)</td>
<td>treatment; while 88% reported at least 50%. 4. In patients in the second group that experienced below level pain, 81% of patients reported 100% pain relief; while 19% that experienced above level pain all achieved 100% pain relief. 5. The intervention did not result in any deaths. 6. 82% of patients lost partial or complete pinprick sensation in the corresponding DREZ. 7. 68% experienced partial or complete loss of light touch sensation.</td>
<td></td>
</tr>
<tr>
<td>Sindou et al. 2001</td>
<td></td>
<td>Case series</td>
<td>N=44</td>
<td>Population: Type of pain=neuropathic and musculoskeletal Treatment: Patients underwent Dorsal Root Entry Zone (DREZ) procedure to reduce pain. <strong>Outcome Measures</strong>: Visual Analogue Scale (VAS)</td>
<td>1. By 10 days, 70% of patients had experienced good pain relief, 18.5% fair pain relief, and 11.5% poor pain relief. 2. 3 months later, 66% reported continued good pain relief. 3. Better pain relief was seen in those with segmental vs. below-lesion pain and in those with conus medullaris vs. higher injuries.</td>
<td></td>
</tr>
<tr>
<td>Spasic et al. 1999</td>
<td></td>
<td>Case series</td>
<td>N=6</td>
<td>Population: Type of pain=neuropathic Treatment: DREZotomy surgical procedure. <strong>Outcome Measures</strong>: Self-reported pain relief.</td>
<td>1. 4/6 patients reported complete pain relief; 2/6 reported 80% pain relief. 2. Two patients who had been using pain medication reported no longer needing them.</td>
<td></td>
</tr>
<tr>
<td>Rath et al. 1997</td>
<td></td>
<td>Case series</td>
<td>N=23</td>
<td>Population: Type of pain=neuropathic Treatment: Patients underwent Dorsal Root Entry Zone (DREZ) procedure. <strong>Outcome Measures</strong>: Patients were asked to judge postoperative pain relative to preoperative pain (%).</td>
<td>1. Of the 23 patients who underwent the procedure, 11 were judged to have experienced good pain relief; the remaining 12 were said to have had a fair or poor result. 2. Better results were seen for those with 'end-zone' vs. diffuse pain.</td>
<td></td>
</tr>
<tr>
<td>Sampson et al. 1995</td>
<td></td>
<td>Case series</td>
<td>N=39</td>
<td>Population: Type of pain=neuropathic and musculoskeletal Treatment: Patients received Dorsal Root Entry Zone (DREZ) procedures from 1978 to 1992. <strong>Outcome Measures</strong>: Pain relief, as indicated by subsequent treatment and activity levels.</td>
<td>1. 21 of the 39 reported good results, while the remaining 18 reported fair results at a mean of 3 yr. 2. 30/39 had no post-operative complications.</td>
<td></td>
</tr>
<tr>
<td>Nashold et al. 1990</td>
<td></td>
<td>Case series</td>
<td></td>
<td>Population: Type of pain=neuropathic and musculoskeletal Treatment: Patients who had a SCI and</td>
<td>1. 14/18 patients reported good pain relief with combined cyst drainage. Good pain relief was defined as not</td>
<td></td>
</tr>
</tbody>
</table>
Discussion

In the Falci et al. (2002) study, individuals were divided into two treatment groups: the first nine patients underwent DREZ micro-coagulation using recorded spontaneous neuro-electrical hyperactivity in as a guide; while the second group underwent DREZ micro-coagulation using both the recorded spontaneous and evoked hyperactivity as a guide. Individuals were followed up to 6 years post-surgery and pain was measured using the VAS. The study found that more participants (50% vs. >80%) in the second group reported 100% pain relief than those in the first group.

Chun et al. (2011) reported on 38 individuals treated with the procedure, between 2003 and 2008. These individuals suffered from various types of neuropathic pain including segmental versus diffuse, mechanical versus thermal or a combination of both, and intermittent versus continuous pain. Previous management with medication had proven unsuccessful. After surgery, individuals were followed for a period ranging between 19 and 84 months (average of 42 months) to measure the degree of pain relief. At follow-up, individuals were asked to rate the intensity of their pain using the VAS. Pain relief was considered by the authors to be “good” if pain was reduced by more than 75%, “fair” if it was reduced by 25-75% and “poor” if pain was reduced less than 25%. Individuals with intermittent pain and continuous pain achieved high rates of good pain relief (78% and 80%, respectively).9

Notably, Nashold et al. (1990) reported 14 of 18 individuals (77%) with paraplegia who underwent cyst drainage and the DREZ surgical procedure reported pain relief following surgery. In general, approximately 50% or more of the patients across these case series achieved greater than 50% pain relief or experienced no pain-related activity limitations and no need for narcotics following the surgery (Friedman & Nashold 1986; Nashold et al. 1990; Rath et al. 1997; Sampson et al. 1995; Sindou et al. 2001; Spaic et al. 1999; Spaic et al. 2002). However, all of these were retrospective, uncontrolled reports with obvious methodological limitations, such as ill-defined eligibility criteria (i.e., potential selection bias) and inadequate outcome measurement which limits the generalizability of the results.

Conclusion

There is level 2 evidence (from one prospective controlled trial, one pre-post study, and seven case series studies; Falci et al. 2002; Chun et al. 2011; Sindou et al. 2001; Spaic et
al. 1999, 2002; Rath et al. 1997; Sampson et al. 1995; Bashold et al. 1990; Friedman & Nashold 1986) to support the use of the DREZ surgical procedure to reduce pain post SCI. It may be that some populations (segmental pain) are more likely to benefit from this procedure.

DREZ surgical procedure reduces pain post SCI.

11.4 Sympathectomy

Sympathectomy is not recommended for pain following SCI (Nashold 1991). As mentioned previously, sympathetic blockade and sympathectomy have reportedly failed to relieve the central pain of SCI (Friedman & Nashold 1986; Melzack & Loeser 1978; White 1969).

11.5 Lateral Spinothalamic Tractotomy

Hazouri and Mueller (1950) described three selected cases of patients with intractable root pain, subsequent to severe trauma to the cauda equina which resulted in paraplegia (L2-4 lesions). All three patients demonstrated a distinct increase in the threshold for perception of pain and "an even more remarkable increase in the threshold for reaction to pain." Lateral spinothalamic tractotomy in all three of these patients resulted in complete relief from pain. Threshold studies subsequent to the tractotomy "revealed a striking return of perception and reaction thresholds to a normal range."

11.6 Spinal Cordotomy

This procedure can be performed openly or percutaneously. Anterior spinothalamic tracts subserving pain and temperature function are sectioned, often requiring a bilateral approach. Spinal cordotomy is an option but is rarely employed and there is little evidence that it works.
12.0 Summary

Pain following SCI is quite common. The most common type of pain post SCI is central or neuropathic in nature characterized by a dysesthetic, burning pain below the level of SCI. Borderzone or segmental pain is much less common; occurring along the border between normal and absent sensation. The precise etiology of central/neuropathic or borderzone segmental pain is not known. There is some evidence suggesting an association may exist between the central or neuropathic dysesthetic burning pain and abnormalities of the sympathetic nervous system. Musculoskeletal pain, either secondary to the original trauma or to overuse is both common and well understood. Unfortunately, the management of central or neuropathic pain remains difficult and largely ineffective.

For many SCI patients, pain has a significant impact on quality of life.

Over 50% of SCI patients develop chronic pain. Severe pain is more common the lower down the lesion in the spinal cord. Pain post SCI most often begins within the first 6-12 months post-SCI.

The most common types of pain post SCI are: 1) a burning pain (likely neuropathic) usually localized to the front of torso, buttock or legs or 2) an aching pain (likely musculoskeletal) usually localized to the neck, shoulders and back.

There is level 2 evidence (from one randomized controlled trial and one prospective controlled trial; Chase et al. 2012; Norrbrink & Lundeberg 2011) that massage therapy may not improve neuropathic and musculoskeletal pain intensity post SCI.

There is level 1b evidence (from one randomized controlled trial; Arienti et al. 2011) that osteopathy alone is not effective in improving neuropathic pain post SCI.

There is level 1a evidence (from two randomized controlled trials; Dyson-Hudson et al. 2001, 2007) that in general acupuncture is no more effective than Trager therapy or sham acupuncture in reducing nociceptive musculoskeletal shoulder pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Yeh et al. 2010) that acupuncture and electroacupuncture reduces neuropathic pain of patients with SCI.

There is level 1b evidence (from one randomized controlled trial; Ginis et al. 2003) that a regular exercise program significantly reduces post-SCI neuropathic and musculoskeletal pain.

There is level 2 evidence (from one prospective controlled trial and one pre-post study; Nawoczenski et al. 2006; Serra-Ano et al. 2012) that a shoulder exercise protocol reduces the intensity of nociceptive shoulder pain post-SCI.

There is level 4 evidence (from one pre-post study; Finley & Rodgers 2007) that the MAGIC wheels 2-gear wheelchair results in less nociceptive shoulder pain.

There is level 2 and level 4 evidence (from one randomized controlled trial and one pre-post study; Jensen et al. 2009, 2000) that hypnosis reduces neuropathic and musculoskeletal pain intensity post SCI.
There is level 4 evidence (from one pre-post study; Jensen et al. 2013) that biofeedback may reduce neuropathic and musculoskeletal pain intensity post SCI.

There is level 2 evidence (from one prospective controlled trial; Perry et al. 2010) that a cognitive behavioural pain management program with pharmacological treatment may improve secondary outcomes among SCI individuals with chronic pain post SCI.

There is level 1b evidence (from one randomized controlled trial one prospective controlled trial, and one pre-post study; Heutink et al. 2012; Norrbrink et al. 2006; Burns et al. 2013) that cognitive-behavioural therapy alone does not change post-SCI pain intensity.

There is conflicting level 1b evidence (from one randomized controlled trial, a cohort study and two pre-post studies; Soler et al. 2010; Kumru et al. 2013; Gustin et al. 2008; Moseley 2007) that visual imagery may reduce at level neuropathic pain post SCI for a short period.

There is strong evidence level 1a evidence (from four randomized controlled trials; Capel et al. 2003; Fregni et al. 2006; Soler et al. 2010; Tan et al. 2006) for the benefits of transcranial electrical stimulation in reducing neuropathic and neuropathic and musculoskeletal post-SCI pain.

There is level 4 evidence (from one pre-post study; Panagos et al. 2004) that using a static field magnet helps to reduce reports of sharp, stabbing nociceptive shoulder pain but does not significantly reduce the VAS score of pain in individuals with a SCI.

There is level 4 evidence (from one case series study; Davis & Lentini 1975) that transcutaneous electrical nerve stimulation reduced at-the-injury site pain in only a minority of patients with thoracic or cauda equina SCI, but not those with cervical SCI.

There is level 1a evidence (from two randomized controlled trials; Jette et al. 2013; Defrin et al. 2007) that transcranial magnetic stimulation significantly reduced post-SCI neuropathic pain significantly over the long-term.

There is level 1a evidence (from two randomized controlled trials, and one case series, pre-post, and observational study; Levendoglu et al. 2004; Tai et al. 2002; To et al. 2002; Ahn et al. 2003; Putzke et al. 2002) that the Gabapentin and pregabalin improve neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Arienti et al. 2011) that combined pregabalin and osteopathy treatment improves pain post SCI.

There is level 4 evidence (from one pre-post study; Ahn et al. 2003) that the anticonvulsant Gabapentin is more effective when SCI pain is<6 months than >6 months.

There is level 1b evidence (from one randomized controlled trial; Finnerup et al. 2002) that lamotrigine improves neuropathic pain in incomplete spinal cord injury.

There is level 1b evidence (from one randomized controlled trial; Finnerup et al. 2009) that Levetiracetam is not effective in reducing neuropathic pain post SCI.
There is level 2 evidence (from one randomized controlled trial; Drewes et al. 1994) that valproic acid does not significantly relieve neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Rintala et al. 2007) that amitriptyline is effective in the treatment of post-SCI neuropathic pain in individuals only when there is concomitant depression.

There is level 1b evidence (from one randomized controlled trial; Vranken et al. 2011) that duloxetine may improve neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Davidoff et al. 1987b) that trazodone does not reduce post-SCI neuropathic pain.

There is level 1b evidence (from one randomized controlled trial; Loubser & Donovan 1991) that Lidocaine delivered through a subarachnoid lumbar catheter provides short-term relief of pain greater than placebo.

There is level 1a evidence (from two randomized controlled trials; Kvarnstrom et al. 2004; Eide et al. 1995) that intravenous Ketamine significantly reduces allodynia when compared to placebo.

There is level 1b evidence (from one randomized controlled trial; Chiou-Tan et al. 1996) that mexilitene (a derivative of lidocaine) does not improve SCI dysesthetic pain when compared to placebo.

There is conflicting level 4 evidence (from two case series studies and one pre-post study; Boviatsis et al. 2005; Plassat et al. 2004; Loubser & Akman 1996) that intrathecal baclofen reduces dysesthetic pain post-SCI.

There is level 4 evidence (from one pre-post study; Loubser & Akman 1996) that intrathecal baclofen reduces musculoskeletal pain post-SCI in conjunction with spasticity reduction.

There is level 4 evidence (from one case series study; Uchikawa et al. 2009) that motor point phenol block is effective in reducing short term spastic shoulder pain post SCI.

There is level 4 evidence (from one case series study; Marciniak et al. 2008) that local botulinum toxin injections to treat focal spasticity reduces pain.

There is level 1b evidence (from one randomized controlled trial; Attal et al. 2002) that intravenous morphine significantly reduces mechanical allodynia more than placebo.

There is level 1b evidence (from one randomized controlled trial; Norrbrink & Lundeberg 2009) that tramadol is effective in reducing neuropathic pain post SCI.

There is level 1b evidence (from one randomized controlled trial; Eide et al. 1995) that alfentanil reduces overall post SCI pain.

There is level 1b evidence (from one randomized controlled trial; Eide et al. 1995) that alfentanil is more effective at reducing wind up like pain than ketamine.
There is level 4 evidence (from one pre-post study; Barrera-Chacon et al. 2010) that oxycodone and anticonvulsants may be effective in improving SCI neuropathic pain.

There is conflicting level 2 evidence (from one randomized controlled trial; Hagenbach et al. 2007) for the use of delta-9-tetrahydrocannabinol in reducing spastic pain in SCI individuals.

There is level 2 evidence ((from one randomized controlled trial; Rintala et al. 2010) that dronabinol is not effective in reducing pain intensity post SCI.

There is level 2 evidence (from one prospective controlled trial; Uhle et al. 2000) that the combination of intrathecal morphine and clonidine provides pain relief greater than placebo.

There is level 4 evidence (from one case series study; Ciono et al. 1995) that spinal cord stimulation improves post-SCI pain.

There is level 3 evidence (from one case control study; Livshits et al. 2002) to support the use of dorsal longitudinal T-myelotomy procedures, in particular Pourpre’s technique, to reduce spastic pain post SCI.

There is level 2 evidence (from one prospective controlled trial, one pre-post study, and seven case series studies; Falci et al. 2002; Chun et al. 2011; Sindou et al. 2001; Spaic et al. 1999, 2002; Rath et al. 1997; Sampson et al. 1995; Bashold et al. 1990; Friedman & Nashold 1986) to support the use of the DREZ surgical procedure to reduce pain post SCI. It may be that some populations (segmental pain) are more likely to benefit from this procedure.
References


Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974;12:175.


Munro D. The care of patients paralyzed as the result of injury to the spinal cord and cauda equina. Med Clin North Am 1948;32:91.


